JP4666440B2 - Amino alcohol derivative - Google Patents
Amino alcohol derivative Download PDFInfo
- Publication number
- JP4666440B2 JP4666440B2 JP2001172689A JP2001172689A JP4666440B2 JP 4666440 B2 JP4666440 B2 JP 4666440B2 JP 2001172689 A JP2001172689 A JP 2001172689A JP 2001172689 A JP2001172689 A JP 2001172689A JP 4666440 B2 JP4666440 B2 JP 4666440B2
- Authority
- JP
- Japan
- Prior art keywords
- group
- substituted
- unsubstituted
- formula
- derivative represented
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 CCCC[C@]1O[C@@]1C(NC(*)Cc1ccccc1)=O Chemical compound CCCC[C@]1O[C@@]1C(NC(*)Cc1ccccc1)=O 0.000 description 3
- URENVOSOXJJAFD-UHFFFAOYSA-N CC(CCC1)C(C)C11C2C1C2 Chemical compound CC(CCC1)C(C)C11C2C1C2 URENVOSOXJJAFD-UHFFFAOYSA-N 0.000 description 1
- TUZZYJUJVXMQAC-UHFFFAOYSA-N CC(CNC)[O]=C Chemical compound CC(CNC)[O]=C TUZZYJUJVXMQAC-UHFFFAOYSA-N 0.000 description 1
- JBCMPTHWXJGFJC-UHFFFAOYSA-N NC1(CCCCC1)C(OCc1ccccc1)=O Chemical compound NC1(CCCCC1)C(OCc1ccccc1)=O JBCMPTHWXJGFJC-UHFFFAOYSA-N 0.000 description 1
- OHAVYOIHGIFRPX-UHFFFAOYSA-N O=C(C1(CCCCC1)NC(N1CCOCC1)=O)OCc1ccccc1 Chemical compound O=C(C1(CCCCC1)NC(N1CCOCC1)=O)OCc1ccccc1 OHAVYOIHGIFRPX-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Pyrrole Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Description
【0001】
【発明の属する技術分野】
本発明は、一般式
【化6】
(式中、R1及びR2は、同一若しくは異なって、置換若しくは無置換の直鎖状、分枝鎖状若しくは環状のアルキル基、置換若しくは無置換の直鎖状、分枝鎖状若しくは環状のアルケニル基、置換若しくは無置換の芳香族炭化水素基又は置換若しくは無置換の複素環基である。R3は置換若しくは無置換の直鎖状、分枝鎖状若しくは環状のアルキル基、置換若しくは無置換の直鎖状、分枝鎖状若しくは環状のアルケニル基、置換若しくは無置換の芳香族炭化水素基、置換若しくは無置換の複素環基、R6−O−又はR7−N(R8)−である。R6は、置換若しくは無置換の直鎖状、分枝鎖状若しくは環状のアルキル基、置換若しくは無置換の直鎖状、分枝鎖状若しくは環状のアルケニル基、置換若しくは無置換の芳香族炭化水素基又は置換若しくは無置換の複素環基である。R7及びR8は同一若しくは異なって、水素原子、置換若しくは無置換の直鎖状、分枝鎖状若しくは環状のアルキル基、置換若しくは無置換の直鎖状、分枝鎖状若しくは環状のアルケニル基、置換若しくは無置換の芳香族炭化水素基又は置換若しくは無置換の複素環基である。さらに、R4及びR5は前記R7及びR8と同一の基を挙げることができ、R4とR5は一体となって環を形成することもできる。Xは−O−又は−N(R9)−であり、R9は水素原子又は置換若しくは無置換の直鎖状、分枝鎖状若しくは環状のアルキル基であり、R4又はR5と一体をなって環を形成することもできる。)で表されるアミノアルコール誘導体に関する。前記一般式(I)で表されるアミノアルコール誘導体は、例えば、プロテアーゼ阻害活性を有するα−ケトアミド誘導体の製造中間体として用いることができる。
【0002】
【従来の技術】
蛋白質分解酵素であるプロテアーゼは、高血圧、血栓、膵炎、癌、アルツハイマー、肺気腫、神経変性疾患、アレルギー性疾患、筋ジストロフィー、リウマチ、骨粗鬆症、歯周病ど多くの疾患の発病、進展に関与することが知られ(蛋白質核酸酵素,42,No14,(1997)、実験医学,17,No15,(1999))、その阻害物質、すなわちプロテアーゼ阻害剤は医薬品のターゲットとして期待されている。
【0003】
これらのプロテアーゼの中でも、セリンプロテアーゼ(エラスターゼ、トリプターゼ、トリプシン、キモトリプシン、プロリルエンドペプチダーゼ)及びシステインプロテアーゼ(カルパイン、カテプシンB、カテプシンL)に対して阻害活性を有することが報告(特開平4−149166、特開平4−211648、特表平6−504547、WO9816512、J.Med.Chem.,39,4089(1996)、Exp.Opin.Ther.Patents.,8,1707(1998))されているα−ケトアミド誘導体は、最近骨代謝に密接に関与することが報告されているカテプシンKに対しても阻害活性を示すことが十分期待される化合物である。
【0004】
このα−ケトアミド構造を有するプロテアーゼ阻害剤の代表的な合成法としては、(A)J.Med.Chem.,36,3472(1993)が、更に光学活性体の合成法として(B)J.Med.Chem.,37,2918(1994)等が知られている。
【0005】
【発明が解決しようとする課題】
前記(A)法は、目的化合物であるα−ケトアミド誘導体を光学活性体として得ることができず、また(B)法は、▲1▼出発原料となる光学活性アミノ酸が高価であること、▲2▼アミノ酸を出発原料としているためR1に限られた置換基しか導入できないこと、▲3▼反応前駆体のα−水酸基を立体選択的に構築することができずジアステレオマー混合物となるため、十分な精製が困難であること、などが問題点であり工業的な製造方法として採用するには満足できるものではなかった。
【0006】
【課題を解決するための手段】
本発明者らは、従来の欠点を克服すべく鋭意検討した結果、R1の置換基がアミノ酸構造に限定されず、かつ、立体選択的にα−ケトアミド誘導体を構築することができる製造原料(前記一般式(I)で表されるアミノアルコール誘導体)を見出し、本発明を完成した。
【0007】
以下、本発明を詳細に説明するにあたって、R1〜R9のアルキル基は、炭素原子数1〜12の直鎖状、分枝鎖状若しくは環状のアルキル基のいずれでもよく、例えば、メチル基、エチル基、n−プロピル基、1−メチルエチル基、シクロプロピル基、n−ブチル基、2−メチルプロピル基、1−メチルプロピル基、1,1−ジメチルエチル基、シクロブチル基、n−ペンチル基、3−メチルブチル基、シクロペンチル基、2,2−ジメチルプロピル基、1−メチルシクロブチル基、シクロブチルメチル基、n−ヘキシル基、4−メチルペンチル基、シクロヘキシル基、1−メチルシクロペンチル基、シクロペンチルメチル基、(1−メチルシクロブチル)メチル基、n−ヘプチル基、5−メチルヘキシル基、4,4−ジメチルペンチル基、シクロヘプチル基、シクロヘキシルメチル基、(1−メチルシクロペンチル)メチル基、n−オクチル基、6−メチルヘプチル基、5,5−ジメチルヘキシル基、(1−メチルシクロヘキシル)メチル基、n−ノニル基、7−メチルオクチル基、6,6−ジメチルヘプチル基、n−デシル基、8−メチルノニル基、7,7−ジメチルオクチル基、n−インデカシル基、9−メチルデシル基、8,8−ジメチルノニル基、n−ドデカシル基、10−メチルウンデカシル基、9,9−ジメチルデカシル基等を挙げることできる。
【0008】
また、R1〜R8の置換又は無置換のアルケニル基は、炭素原子数2〜6の直鎖状、分枝鎖状又は環状のアルケニル基のいずれでもよく、例えば、1−メチル−1−プロペニル基、1−メチル−2−プロペニル基、2−メチル−2−プロペニル基、エテニル基、1−メチルエテニル基、1−プロペニル基、2−プロペニル基、1−ブテニル基、2−ブテニル基、2−ペンテニル基、1−ペンテニル基、1,3−ブタンジエニル基、1−ヘキセニル基、2−ヘキセニル基、1,3−ペンタジエニル基、1,3−ヘキサジエニル基等を挙げることができる。このアルケニル基の置換基としては、置換又は無置換の芳香族炭化水素基、置換又は無置換の複素環基等を挙げることができる。
【0009】
R1〜R8の置換又は無置換の芳香族炭化水素基は、単環式若しくは多環式であり、さらに環上に1個以上の種々の置換基を有していてもよい芳香族炭化水素基をいい、例えば、フェニル基、4−メチルフェニル基、3,4−ジメチルフェニル基、4−メトキシフェニル基、2,3−ジメトキシフェニル基、3,4−ジメトキシフェニル基、3,5−ジメトキシフェニル基、2,3−メチレンジオキシフェニル基、3,4−メチレンジオキシフェニル基、4−ニトロフェニル基、3,4−ジニトロフェニル基、4−クロロフェニル基、3,4−ジクロロフェニル基、4−ブロモフェニル基、3,4−ジブロモフェニル基、4−ヨ−ドフェニル基、4−フルオロフェニル基、2,3−ジフルオロフェニル基、3,4−ジフルオロフェニル基、3,5−ジフルオロフェニル基、4−トリフルオロメチルフェニル基、3−フェノキシフェニル基、4−フェノキシフェニル基、4−(1−ナフトキシ)フェニル基、4−アセトアミノフェニル基、1−ナフチル基、2−ナフチル基等を挙げることができる。
【0010】
R1〜R8の置換又は無置換の複素環基は、環構成原子として窒素原子、硫黄原子、酸素原子等のヘテロ原子を少なくとも1以上含む5員環又は6員環の基であり、これらはベンゼン環と縮合していてもよく、例えば、2−ピリジル基、2−フリル基、2−チエニル基、2−インドリル基、2−キノリル基、3−イソキノリル基、2−ベンゾフラニル基、2−ベンゾチエニル基、2−イミダゾリル基、2−ベンズイミダゾリル基、2−チアゾリル基、2−オキサゾリル基、2−ピラゾリル基、2−ピリミジル基、2−ピリミジニル基、2−ジオキサニル基、2−チアゾリジニル基、2−イミダゾリジニル基、2−オキソテトラヒドロフラン−3−イル基、2−ベンゾチアゾリル基、2−キナゾリン基、ヘキサヒドロ−2−アゼノピン−3−イル基、モルホリノ基、チアモルホリノ基、ピロリジノ基、ピペリジノ基、ピペラジノ基、ペルヒドロ−4−アゼピン−1−イル基、ペルヒドロ−4−アザアゼピン−1−イル基等を挙げることができる。この複素環上には1個以上の置換基を有していてもよく、置換基としては、例えば、アセチル基、メトキシカルボニル基、エトキシカルボニル基、2−メチル−2−プロピルオキシカルボニル基、メチルスルホニル基、メトキシ基、ベンゾイル基等を挙げることができる。
【0011】
このアルキル基への置換基としては、例えば、水酸基、オキソ基、ハロゲン原子、置換又は無置換の炭素原子数2〜6の直鎖状、分枝鎖状又は環状のアルケニル基、置換又は無置換の芳香族炭化水素基、置換又は無置換の複素環基、ニトロ基、置換又は無置換のアミノ基、置換又は無置換のスルホニル基、置換又は無置換のアルコキシル基、置換又は無置換のアルキルチオ基、置換又は無置換のアリールオキシ基、置換又は無置換のアリールチオ基、アシル基、置換又は無置換のアルコキシカルボニル基、置換カルバモイル基、置換スルホンアミド基、置換アミド基、メルカプト基、シアノ基等を挙げることができる。
【0012】
ここで、R1〜R8のアルキル基への置換基として挙げられたアルケニル基は、前記したアルケニル基と同一の基を挙げることができる。
【0013】
また、R1〜R8のアルキル基又はアルケニル基への置換基である、置換又は無置換の芳香族炭化水素基は、前記した芳香族炭化水素基と同一の基を挙げることができる。
【0014】
R1〜R8のアルキル基又はアルケニル基への置換基である、置換又は無置換の複素環基は、前記した複素環基と同一の基を挙げることができる。
【0015】
R1〜R8のアルキル基への置換基である、置換アミノ基は、種々の置換基により置換されている第二級アミノ基又は第三級アミノ基をいい、これらの置換基としては、前記した置換又は無置換のアルキル基、置換又は無置換のアルケニル基、置換又は無置換の芳香族炭化水素基、置換又は無置換の複素環基と同一の基を挙げることができる。
【0016】
R1〜R8のアルキル基への置換基である、置換スルホニル基としては、例えば、メチルスルホニル基、n−ブチルスルホニル基、2,2−ジメチルエチルスルホニル基、シクロヘキシルスルホニル基、フェニルスルホニル基、4−メチルフェニルスルホニル基、4−フルオロフェニルスルホニル基、4−クロロフェニルスルホニル基、4−ニトロフェニルスルホニル基、2−ナフチルスルホニル基、3,4−ジメトキシフェニルスルホニル基、3,4−メチレンジオキシフェニルスルホニル基、2−ピリジルスルホニル基、2−フリルスルホニル基、2−チエニルスルホニル基、2−キノリルスルホニル基、3−イソキノリルスルホニル基、フェニルメチルスルホニル基、4−フルオロフェニルメチルスルホニル基、4−クロロフェニルメチルスルホニル基、4−ニトロフェニルメチルスルホニル基、2−ナフチルメチルスルホニル基、3,4−ジメトキシフェニルメチルスルホニル基、3,4−メチレンジオキシフェニルメチルスルホニル基等を挙げることができる。
【0017】
R1〜R8のアルキル基への置換基である、アルコシキ基は、アルキル部分が前記の炭素原子数1〜6のアルキル置換オキシ基であり、例えばメトキシ基、エトキシ基、n−プロポキシ基、1−メチルエチルオキシ基、n−ブトキシ基、2−メチルプロピルオキシ基、1−メチルプロピルオキシ基、2−メチル−2−プロピルオキシ基、2,2−ジメチルエチルオキシ基、n−ペンチルオキシ基、3−メチルブチルオキシ基、n−ヘキシルオキシ基、4−メチルペンチルオキシ基、シクロヘキシルオキシ基等を挙げることができる。このアルコキシル基の置換基としては、前記したアルケニル基への置換基と同一の基を挙げることができる。
【0018】
R1〜R8のアルキル基への置換基である、アルキルチオ基は、アルキル部分が前記の炭素原子数1〜6のアルキル置換チオ基であり、例えば、メチルチオ基、エチルチオ基、n−プロピルチオ基、1−メチルエチルチオ基、n−ブチルチオ基、2−メチルプロピルチオ基、1−メチルプロピルチオ基、2−メチル−2−プロピルチオ基、2,2−ジメチルエチルチオ基、n−ペンチルチオ基、3−メチルブチルチオ基、n−ヘキシルチオ基、4−メチルペンチルチオ基、シクロヘキシルチオ基等を挙げることができる。さらに、このアルキルチオ基の置換基としては、前記したアルケニル基への置換基と同一の基を挙げることができる。
【0019】
R1〜R8のアルキル基への置換基である、置換又は無置換のアリールオキシ基としては、例えばフェニルオキシ基、4−メチルフェニルオキシ基、4−フルオロフェニルオキシ基、4−クロロフェニルオキシ基、4−ニトロフェニルオキシ基、2−ナフチルオキシ基、3,4−ジメトキシフェニルオキシ基、3,4−メチレンジオキシフェニルオキシ基、2−ピリジルオキシ基、2−フリルオキシ基、2−チエニルオキシ基、2−キノリルオキシ基、3−イソキノリルオキシ基、4−ニトロフェニルメチルオキシ基、2−ナフチルメチルオキシ基、3,4−ジメトキシフェニルオキシ基、3,4−メチレンジオキシフェニルメチルオキシ基等を挙げることができる。
【0020】
R1〜R8のアルキル基への置換基である、置換又は無置換のアリールチオ基としては、例えばフェニルチオ基、4−メチルフェニルチオ基、4−フルオロフェニルチオ基、4−クロロフェニルチオ基、4−ニトロフェニルチオ基、2−ナフチルチオ基、3,4−ジメトキシフェニルチオ基、3,4−メチレンジオキシフェニルチオ基、2−ピリジルチオ基、2−フリルチオ基、2−チエニルチオ基、2−キノリルチオ基、3−イソキノリルチオ基、フェニルメチルチオ基、4−フルオロフェニルメチルチオ基、4−クロロフェニルメチルチオ基、4−ニトロフェニルメチルチオ基、2−ナフチルメチルチオ基、3,4−ジメトキシフェニルメチルチオ基、3,4−メチレンジオキシフェニルメチルチオ基等を挙げることができる。
【0021】
R1〜R8のアルキル基への置換基である、置換又は無置換のアルコキシカルボニル基は、例えばメトキシカルボニル基、エトキシカルボニル基、n−プロポキシカルボニル基、n−ブトキシカルボニル基、2,2−ジメチルエチルオキシカルボニル基、シクロヘキシルオキシカルボニル基、フェニルメチルオキシカルボニル基等を挙げることができる。
【0022】
R1〜R8のアルキル基への置換基である、置換カルバモイル基は、カルバモイル結合基の窒素原子に種々の置換基が結合したR3−NHCO−で表される基をいい、ここで窒素原子に結合した置換基R3としては前記した置換又は無置換のアルキル基、置換又は無置換のアルケニル基、置換又は無置換の芳香族炭化水素基、置換又は無置換の複素環基、置換又は無置換のアミノ基等を挙げることができ、例えば、N−メチルカルバモイル基、N,N−ジメチルカルバモイル基、N−ブチルカルバモイル基、N,N−ジブチルカルバモイル基、N−(2,2−ジメチルエチル)カルバモイル基、N−シクロヘキシルカルバモイル基、N−フェニルカルバモイル基、N−(4−メチルフェニル)カルバモイル基、N−(4−フルオロフェニル)カルバモイル基、N−(4−クロロフェニル)カルバモイル基、N−(4−ニトロフェニル)カルバモイル基、N,N−ジフェニルカルバモイル基、N−ナフチルカルバモイル基、N−(3,4−ジメトキシフェニル)カルバモイル基、N−(3,4−メチレンジオキシフェニル)カルバモイル基、N−メチル−N−フェニルカルバモイル基、N−メチル−N−ナフチルカルバモイル基、N−(2−ピリジル)カルバモイル基、N−(2−フリル)カルバモイル基、N−(2−チエニル)カルバモイル基、N−(2−キノリル)カルバモイル基、N−(3−イソキノリル)カルバモイル基、N−(フェニルメチル)カルバモイル基、N−(4−フルオロフェニルメチル)カルバモイル基、N−(4−クロロフェニルメチル)カルバモイル基、N−(4−ニトロフェニルメチル)カルバモイル基、N−(ナフチルメチル)カルバモイル基、N−(3,4−ジメトキシフェニルメチル)カルバモイル基、N−(3,4−メチレンジオキシフェニルメチル)カルバモイル基等を挙げることができる。
【0023】
R1〜R8のアルキル基への置換基である、置換スルホンアミド基は、スルホンアミド結合基の硫黄原子に種々の置換基が結合したR4−SO2 NH−で表される基をいい、ここで硫黄原子に結合した置換基R4としては前記した置換又は無置換のアルキル基、置換又は無置換のアルケニル基、置換又は無置換の芳香族炭化水素基、置換又は無置換の複素環基、置換又は無置換のアミノ基等を挙げることができる。
【0024】
R1〜R8のアルキル基への置換基である、置換アミド基は、アミド結合基の炭素原子に種々の置換基が結合したR5−CONH−で表される基をいい、ここで炭素原子に結合した置換基R5としては、フェノキシ基、1−ナフチルオキシ基、2−ナフチルオキシ基、前記した置換又は無置換のアルキル基、置換又は無置換のアルケニル基、置換又は無置換の芳香族炭化水素基、置換又は無置換の複素環基、置換又は無置換のアミノ基、置換又は無置換アルコキシル基等を挙げることができる。
【0025】
R4とR5とが一体となって形成される環は、炭素原子数5〜7の飽和環状アルキル基又はヘテロ原子を含む炭素原子数3〜6の飽和複素環基である。炭素原子数5〜7の飽和環状アルキル基としては、例えば、シクロペンタン、シクロヘキサン、シクロヘプタン等から誘導される基を挙げることができる。また、ヘテロ原子を含む炭素原子数3〜6の飽和複素環基としては、例えば、ピロリジン、ピペリジン、ピペラジン、モルホリン、パーヒドロアゼピン、オキソラン、オキサン、オキセパン、チオラン、チアン、チエパン等から誘導される基を挙げることができ、ヘテロ原子としては、酸素原子、硫黄原子、窒素原子等を挙げることができる。また、ヘテロ原子を含む炭素原子数3〜6の飽和複素環基はベンゼン環と縮合することもできる。これらの炭素原子数5〜7の飽和環状アルキル基及びヘテロ原子を含む炭素原子数3〜6の飽和複素環基は置換基を有していてもよく、その置換基としては、例えば、水酸基、ハロゲン原子、置換又は無置換のアルキル基、フェニル基、メチルフェニル基、ナフチル基等の置換又は無置換の芳香族炭化水素基、チエニル基、フリル基、ピリジル基等の置換又は無置換の複素環基、ニトロ基、置換又は無置換のアミノ基、置換又は無置換のスルホニル基、置換又は無置換のアルコキシル基、置換又は無置換のアルキルチオ基、置換又は無置換のアリールオキシ基、置換又は無置換のアリールチオ基、アシル基、置換又は無置換のアルコキシカルボニル基、置換カルボニル基、メルカプト基、シアノ基等の前記した基と同一の基を挙げることができる。
【0026】
また、R9と、R4又はR5が一体となって形成される環は、窒素原子を含む炭素原子数3〜6の飽和複素環基である。窒素原子を含む炭素原子数3〜6の飽和複素環基としては、例えば、ピロリジン、ピペリジン、ピペラジン、モルホリン、パーヒドロアゼピン等から誘導される基を挙げることができ、ベンゼン環と縮合することもできる。この飽和複素環基は置換基を有していてもよく、その置換基としては、例えば、水酸基、ハロゲン原子、置換又は無置換のアルキル基、フェニル基、メチルフェニル基、ナフチル基等の置換又は無置換の芳香族炭化水素基、チエニル基、フリル基、ピリジル基等の置換又は無置換の複素環基、ニトロ基、置換又は無置換のアミノ基、置換又は無置換のスルホニル基、置換又は無置換のアルコキシル基、置換又は無置換のアルキルチオ基、置換又は無置換のアリールオキシ基、置換又は無置換のアリールチオ基、アシル基、置換又は無置換のアルコキシカルボニル基、置換カルボニル基、メルカプト基、シアノ基等の前記した基と同一の基を挙げることができる。
【0027】
前記一般式(I)で表されるアミノアルコール誘導体は、下式に従い製造することができる。
【化7】
(式中、R1〜R5は前記一般式(I)のR1〜R5と同じである。)
【0028】
本工程は、前記一般式(II)で表されるアミン誘導体と前記一般式(III)で表されるカルボン酸誘導体とを縮合することにより、立体構造を保持して、前記一般式(I)で表されるアミノアルコール誘導体を製造する工程である。
【0029】
本工程の前記一般式(III)で表されるカルボン酸誘導体は、トリエチルアミン、ピリジン、ジメチルアミノピリジン等の塩基存在下、カルボキシル基をピバロイルクロリド、クロル炭酸イソブチル、クロル炭酸エチル、p−トルエンスルホニルクロリド、メタンスルホニルクロリド等を用いて混合酸無水物に変換した後、前記一般式(II)で表されるアミン誘導体と縮合することができる。反応は不活性溶媒中で行うことが望ましく、例えばジクロロメタン、クロロホルム、ジクロロエタン等のハロゲン化炭化水素類、ベンゼン、トルエン、キシレン等の芳香族炭化水素類、ジエチルエーテル、ジメトキシエタン、テトラヒドロフラン、ジオキサン等のエーテル類、ジメチルホルムアミド、アセトニトリル、酢酸エチル等を単独又は混合して使用することができる。反応温度は、−20℃〜40℃で実施することができる。
また、カルボン酸誘導体(III)とアミン誘導体(II)との反応は、縮合剤の存在下に行うことでき、縮合剤としては、例えばジシクロヘキシルカルボジイミド、1−エチル−3−(3−ジメチルアミノプロピル)カルボジイミド、イソプロピルカルボジイミド等のカルボジイミド試薬を用いることができる。
さらに本工程は、前記縮合剤を用いて、カルボン酸誘導体(III)とN−ヒドロキシスクシンイミド、p−ニトロフェノール、1−ヒドロキシベンゾトリアゾール等を縮合して活性エステル体とした後、アミン誘導体(II)と反応させることもできる。
【0030】
この工程は、アミン誘導体(IIa〜IId)の各立体構造に対応し、立体構造を保持して下表に示すアミノアルコール誘導体(Ia〜Id)を製造することができる。
【表1】
(表中、R1〜R5は、前記一般式(I)のR1〜R5と同じである。)
【0031】
前記一般式(II)で表される製造原料は、下式に従い立体選択的に製造することができる。
【化8】
(式中、R1及びR2は、前記一般式(I)のR1及びR2と同じである。)
【0032】
(第2−1工程)
本工程は、前記一般式(IV)で表されるアルコール誘導体を酸化し、前記一般式(V)で表されるエポキシアルコール誘導体を製造する工程である。
【0033】
この工程で用いる酸化反応としては、例えばSharpless酸化法を用いることができる。酸化剤としては、t−ブチルヒドロペルオキシド、クメンヒドロペルオキシド、トリチルヒドロペルオキシド等を、触媒としてはチタンテトライソプロポキシド等を用いることができる。また、不斉源試薬としては、例えば、D−(−)−酒石酸ジイソプロピル、酒石酸ジエチル、酒石酸ジメチル等の光学活性体の酒石酸エステルを用いることができる。反応は不活性溶媒中で行うことが望ましく、例えばジクロロメタン、クロロホルム、ジクロロエタン等のハロゲン化炭化水素類、ベンゼン、トルエン、キシレン等の芳香族炭化水素類を使用することができる。尚、反応は、−40℃から徐々に室温にあげることにより実施することができる。
【0034】
この工程は、アルコール誘導体(IV)及び不斉試薬の立体構造により、下表に示す4種のエポキシアルコール誘導体(V)を立体選択的に製造することができる。
【表2】
(表中、R1は前記一般式(I)のR1と同じである。)
【0035】
(第2−2工程)
本工程は、前記一般式(V)で表されるエポキシアルコール誘導体を酸化することにより、立体構造を保持して、前記一般式(VI)で表されるエポキシカルボン酸誘導体を製造する工程である。
【0036】
本工程の前記一般式(V)で表されるエポキシアルコール誘導体を酸化する反応は、酸化剤として、過ヨウ素ナトリウム、過ヨウ素酸等の酸化試薬を、触媒として塩化ルテニウムを用いることができる。反応溶媒は、アセトニトリル/四塩化炭素/水の混合溶媒を用いることが望ましく、反応温度は、−10℃〜30℃で実施することができる。
【0037】
(第2−3工程)
本工程は、前記一般式(VI)で表されるエポキシカルボン酸誘導体とアミン体(VII)を縮合することにより、立体構造を保持して、前記一般式(VIII)で表されるエポキシカルボン酸アミド誘導体を製造する工程である。
【0038】
本工程は、縮合反応であり、前記第1工程と同じ縮合剤を用い、同じ反応試薬及び反応条件により製造を行うことができる。
【0039】
(第2−4工程)
本工程は、前記一般式(VIII)で表されるエポキシカルボン酸アミド誘導体を、位置選択的に開環することにより、立体選択的に前記一般式(IX)で表されるアジド誘導体を製造する工程である。
【0040】
この工程で用いる開環試薬としては、アジ化ナトリウム−無水硫酸マグネシウムを用いることができ、無水硫酸マグネシウムの代わりに塩化アンモニウムを用いることができる。また、反応溶媒は、例えばメタノール、エタノール、プロパノール、2−メトキシエタノール等のアルコール溶媒、アセトニトリル等を用いることができる。尚、反応は、50℃〜150℃で実施することができる。
【0041】
この工程は、エポキシカルボン酸アミド誘導体(VIII)の各立体構造に対応して、立体選択的に下表に示すアジド誘導体(IX)を製造することができる。
【表3】
(表中、R1及びR2は、前記一般式(I)のR1及びR2と同じである。)
【0042】
(第2−5工程)
本工程は、前記一般式(IX)で表されるアジド誘導体を還元することにより、立体構造を保持して、前記一般式(II)で表されるアミン誘導体を製造する工程である。
【0043】
この工程で用いる還元反応としては、接触還元法を用いることができ、触媒として、例えばPd−C、Pd−黒等を使用することができる。反応溶媒はメタノール、エタノール等のアルコール溶媒を用いることができ、反応温度は、室温から40℃で行うことができる。また、本工程は、トリフェニルホスフィンと水を用いて還元することもでき、反応溶媒としてはテトラヒドロフラン、ジオキサン等のエーテル系溶媒を用いることが好ましい。
【0044】
また、前記一般式(III)で表される製造原料は、Xが−N(R9)−の場合には市販アミノ酸のアミノ基を保護することにより得ることができる(泉屋ら「ペプチド合成の基礎と実験」(1986)丸善株式会社)。また、Xが−O−の場合には、文献(J.Am.Chem.Soc.,86,5326(1964)、J.Am.Chem.Soc.,112,7659(1990))の方法に準じて合成することができる。
【0045】
前記一般式(I)で表されるアミノアルコール誘導体は、例えば下式の反応に供することにより、カテプシンK阻害活性を有するα−ケトアミド誘導体(X)に導くことができる。
【化9】
(式中、R1〜R5は前記一般式(I)のR1〜R5と同じである。)
【0046】
本工程は、前記一般式(I)で表されるアミノアルコール誘導体を酸化し、前記一般式(X)で表されるα−ケトアミド誘導体を製造する工程である。
【0047】
この工程で用いる酸化反応としては、例えば活性ジメチルスルホキシド酸化法を用いることができる。酸化剤としては、ジメチルスルホキシドを用い、ジシクロヘキシルカルボジイミド、五酸化リン、ピリジン−三酸化イオウ錯体、塩化オギザリル、無水酢酸、トリフルオロ酢酸等の活性化剤を合わせて使用する。活性化剤の使用量は、前記一般式(I)で表されるアミノアルコール誘導体に対して1〜12当量用いることができる。また、反応は溶媒中で行うことが好ましく、例えばジクロロメタン、クロロホルム、ジクロロエタン等のハロゲン化炭化水素類を用いることができるが、酸化剤として用いるジメチルスルホキシドを過剰量用い溶媒とすることもできる。反応は、−78℃〜30℃で実施することができる。
【0048】
この工程は、アミノアルコール誘導体(I)の各立体構造に対応し、R1の立体構造を保持して下表に示すα−ケトアミド誘導体(X)を製造することができる。
【表4】
(表中、R1〜R5は、前記一般式(I)のR1〜R5と同じである。)
【発明の実施の形態】
以下、参考例及び実施例により本発明をさらに詳細に説明する。
【0049】
参考例1
1−アミノシクロヘキサンカルボン酸 フェニルメチルエステル・p−トルエンスルホン酸塩の合成
【化10】
1−アミノシクロヘキサンカルボン酸50.8g(355mmol)、p−トルエンスルホン酸一水和物81g(426mmol)、ベンジルアルコール180ml及びトルエン360mlをフラスコにいれ、還流冷却器をつけたDean−Stark装置を用いて油浴(160℃)中一晩加熱した。生成する水はトルエンとの共沸により除去した。反応終了後、反応液を大量の酢酸エチルにあけると、結晶が析出した。この結晶を再度酢酸エチルで洗浄して、標記化合物を128g(89%)得た。
【0050】
1H−NMR(CDCl3, δ):1.25−1.43(2H, m), 1.43−1.58(2H, m), 1.59−1.70(2H, m), 1.83−1.94(2H, m), 1.94−2.02(2H, m), 2.83(3H, s), 5.13(2H, s), 7.10(2H, d, J=8Hz), 7.24−7.31(5H, m), 7.76(2H, d, J=8Hz), 8.30(2H, brs)
IR(ν, KBr, cm-1):3468, 1746, 1608
FAB−Mass(m/z,%):406(M++1, 2), 234(100)
【0051】
参考例2
1−[N−(モルホリン−4−カルボニル)アミノ]シクロヘキサンカルボン酸フェニルメチルエステルの合成
【化11】
1−アミノシクロヘキサンカルボン酸 フェニルメチルエステル p−トルエンスルホン酸塩203g(500mmol)を10%炭酸ナトリウム溶液で中和後クロロホルムで抽出し、無水硫酸マグネシウムで乾燥した。固形物を濾過し、このクロロホルム層にトリエチルアミン56g(550mmol)を加えた後、4−モルホリンカルボニルクロリド75g(500mmol)を滴下し、油浴(60℃)中3日間加温した。反応終了後、反応溶液を、水、10%硫酸水素カリウム水溶液、飽和炭酸水素ナトリウム水溶液、飽和食塩水の順に洗浄し、無水硫酸ナトリウムで乾燥した。減圧下で溶媒を留去した後、得られた結晶をエーテルで洗浄して標記化合物を151g(87%)得た。
【0052】
1H−NMR(CDCl3, δ):1.22−1.88(6H, m), 1.85−1.92(2H, m), 2.07−2.30(2H, m), 3.45(4H, t, J=5Hz), 3.67(4H, t, J=5Hz), 4.53(1H, s), 5.15(2H, s), 7.31−7.34(5H, m)
IR(ν, KBr, cm-1):3316, 1732, 1690
FAB−Mass(m/z,%):347(M++1, 100), 234(44)
【0053】
参考例3
1−[N−(モルホリン−4−カルボニル)アミノ]シクロヘキサンカルボン酸の合成
【化12】
1−[N−(モルホリン−4−カルボニル)アミノ]シクロヘキサンカルボン酸 フェニルメチルエステル151g(452mmol)をメタノールに懸濁させ、5%パラジウム−活性炭素15gを加え、水素気流下室温で1晩撹拌させた。触媒を濾過した後、触媒をクロロホルム−メタノールの混合溶媒で3度洗浄し、有機層を合わせて減圧下で留去し標記化合物112g(100%)得た。
【0054】
1H−NMR(CDCl3, δ):1.35−1.39(3H, m), 1.64−1.72(3H, m), 1.91−1.97(2H, m), 2.06−2.10(2H, m), 3.43(4H, t, J=5Hz), 3.73(4H, t, J=5Hz), 4.50(1H, s)
IR(ν, KBr, cm-1):3824, 2568, 1970
FAB−Mass(m/z,%):257(M++1, 8), 98(100)
【0055】
参考例4
2−ヘプチン−1−オールの合成
【化13】
リチウム6.0g(0.9mol)を硝酸鉄(III)九水和物180mg(0.45mmol)の液体アンモニア300ml溶液に−30〜−40℃で加えた。さらに同温で2−プロピン−1−オール25.2g(0.45mol)のエーテル溶液(20ml)を加え1.5時間撹拌後、n−ブチルブロマイド41.1g(0.30mol)を加えた。反応溶液を室温に戻し一夜撹拌した。反応終了後、飽和塩化アンモニウム水溶液を加え、エーテル(500ml)で抽出した。有機層を飽和食塩水で洗浄し、無水硫酸ナトリウムで乾燥後、溶媒を減圧留去した。残留物を減圧蒸留し、標記化合物、21.0g(62.4%)を得た。
【0056】
1H−NMR(CDCl3, δ):0.91(3H, t, J=7Hz), 1.36−1.54(5H, m),2.22(2H, tt, J=7Hz, 2Hz), 4.25(1H, dt, J=6Hz, 2Hz)
【0057】
参考例5
(trans)− 2−ヘプテン−1−オールの合成
【化14】
氷冷下、65%水素化ビス(2−メトキシエトキシ)アルミニウムナトリウム(Red−Al)トルエン溶液16ml(53.49mmol)を 2−ヘプチン−1−オール4.0g(35.66mmol)のトルエン溶液(5ml)に加え、室温に戻し3時間撹拌した。反応終了後、氷水を加え石油エーテル(50ml)で抽出した。有機層を飽和食塩水で洗浄し、無水硫酸ナトリウムで乾燥後、溶媒を減圧留去した。残留物を減圧蒸留し、標記化合物、3.3g(80.6%)を得た。
【0058】
1H−NMR(CDCl3, δ):0.90(3H, t, J=7Hz), 1.27−1.41(5H, m), 2.31(2H, dt, J=7Hz, 6Hz), 4.09(2H, dd, J=5Hz,5Hz), 5.60−5.74(2H, m)
【0059】
参考例6
(2R−trans)−3−ブチルオキシランメタノールの合成
【化15】
アルゴン雰囲気下、モレキュラーシーブス4A3.4gの無水塩化メチレン懸濁液(150ml)にD−(−)−酒石酸ジイソプロピル3.3g(14.08mmol)、チタンテトライソプロポキシド3.3g(11.73mmol)及び2−ヘプテン−1−オール13.4g(117.30mmol)を−30〜−40℃で加え10分間撹拌した。反応溶液を−60℃に冷却し、撹拌下、2.23M t−ブチルヒドロペルオキシドのトルエン溶液105mlを20分で滴下し、2時間かけて室温に戻した。反応終了後、反応液を硫酸鉄(III)七水和物(80g)及びL−酒石酸(40g)の水溶液(400ml)に加え、塩化メチレン(400ml)で抽出した。有機層を飽和食塩水で洗浄し、無水硫酸ナトリウムで乾燥後、溶媒を減圧留去した。残留物にエーテル(400ml)及び1N−水酸化ナトリウム(200ml)を加え、室温で1時間撹拌した。反応終了後、有機層を分離し、水層をエーテル(50ml)で抽出した。有機層を飽和食塩水で洗浄し、無水硫酸ナトリウムで乾燥後、溶媒を減圧留去した。残留物を減圧蒸留し、標記化合物、11.6g(76.2%)を得た。
【0060】
1H−NMR(CDCl3, δ):0.92(3H, t, J=7Hz), 1.34−1.48(4H, m), 1.56−1.61(2H, m), 1.73(1H, brs), 2.91−2.98(2H, m), 3.63(1H, ddd, J=12Hz, 8Hz, 4Hz), 3.92(1H, ddd, J=12Hz, 6Hz, 3Hz)IR(ν,NaCl(film), cm-1):3456,2936,2864,1470,1030,880
FAB−Mass(m/z,%):131(M++1, 58), 113(84),95(100), 69(93)
【0061】
参考例7
(2S−trans)−3−ブチル−オキシランカルボン酸・ジシクロヘキシルアミン塩の合成
【化16】
氷冷下、(2R−trans)−3−ブチルオキシランメタノール1.30g(10mmol)のアセトニトリル20ml、四塩化炭素20ml、水30mlの混合溶液に過ヨウ素酸5.70g(25mmol)、次いで塩化ルテニウムn水和物41mgを加えた後、室温にて1時間撹拌した。反応液に酢酸エチルを加え、水更に飽和食塩水で洗浄後、無水硫酸マグネシウムで乾燥した。不溶物を濾過し、濾液にジシクロヘキシルアミン1.63g(9mmol)を加えた後、減圧下にて溶媒を留去した。得られた残留物に石油エーテルを加えて2時間撹拌した。結晶を濾取し、更に石油エーテルで洗浄して標記化合物2.30g(70%)を得た。
【0062】
1H−NMR(CDCl3, δ): 0.91(3H, t, J=7Hz), 1.10−1.30(6H, m), 1.31−1.57(9H, m), 1.58−1.71(3H, m), 1.74−1.82(4H, m), 1.96−2.04(4H, m), 2.90−2.94(1H,m), 2.97−3.06(2H, m), 3.08(1H, d, J=2Hz)
IR(ν, KBr, cm-1):2932, 2856, 1604, 1400
FAB−Mass(m/z,%):326(M++1, 7), 182(100)
【0063】
参考例8
(2S−trans)−N−[(1S,2S)−2−ヒドロキシシクロヘキサン−1−イル]−3−ブチルオキシランカルボキサミドの合成
【化17】
氷冷下、(2S−trans)−3−ブチル−オキシランカルボン酸、ジシクロヘキシルアミン塩2.3g(7mmol)の無水テトラヒドロフラン20ml溶液にピバロイルクロリド844mg(7mmol)の無水テトラヒドロフラン2ml溶液を加え、同温度で15分間撹拌した。さらに反応液を室温に戻して2時間撹拌した。反応液中の不溶物を濾過後、氷冷下、(1S,2S)−2−アミノシクロヘキサノール806mg(7mmol)の無水テトラヒドロフラン20ml溶液に加え、室温にて2時間撹拌した。減圧下、反応液を濃縮して酢酸エチルを加え、10%硫酸水素カリウム水溶液、飽和炭酸水素ナトリウム水溶液次いで飽和食塩水で洗浄した。有機層を無水硫酸マグネシウムで乾燥後、減圧下で溶媒を留去して標記化合物1.69g(100%)を得た。
【0064】
1H−NMR(CDCl3, δ): 0.92(3H, t, J=7Hz), 1.11−1.48(8H, m), 1.52−1.62(1H, m ), 1.64− 1.76(3H, m), 1.83−1.89(1H, m), 2.03−2.10(1H, m), 2.90−2.95(1H, m), 3.27(1H, d, J=2Hz), 3.30−3.38(1H, m), 3.54−3.65(1H, m), 6.13(1H, d, J=8Hz)
IR(ν, KBr, cm-1):2932, 2860, 1650
FAB−Mass(m/z,%):242(M++1, 100), 98(95)
【0065】
参考例9
(2S,3S)−N−[(1S,2S)−2−ヒドロキシシクロヘキサン−1−イル]−3−アジド−2−ヒドロキシヘプタンアミドの合成
【化18】
(2S)−trans−N−[(1S,2S)−2−ヒドロキシシクロヘキサン−1−イル]−3−ブチルオキシランカルボキサミド1.64g(7mmol)、アジ化ナトリウム910mg(14mmol)及び無水硫酸マグネシウム868mg(7.2mmol)のメタノール 30ml懸濁液を5時間加熱還流した。反応液を室温に戻した後、300mlの水にあけ2時間撹拌した。結晶を濾取しさらに水で洗浄後、乾燥して標記化合物1.45g(73%)を得た。
【0066】
1H−NMR(CDCl3, δ):0.91(3H, t, J=7Hz), 1.19−1.53(9H, m), 1.58−1.78(3H, m), 1.89− 1.98(1H, m), 2.03−2.11(1H, m), 3.31−3.39(1H, m), 3.52(1H, d, J=6Hz), 3.61−3.71(2H, m), 4.15(1H, d, J=4Hz), 4.29(1H, t, J=4Hz), 6.78(1H, d, J=8Hz)
IR(ν, KBr, cm-1):2936, 2864, 2096, 1636
FAB−Mass(m/z,%):285(M++1, 100), 116(97)
【0067】
参考例10
(2S,3S)−N−[(1S,2S)−2−ヒドロキシシクロヘキサン−1−イル]−3−アミノ−2−ヒドロキシヘプタンアミドの合成
【化19】
(2S,3S)−N−[(1S,2S)−2−ヒドロキシシクロヘキサン−1−イル]−3−アジド−2−ヒドロキシヘプタンアミド1.45g(5mmol)のメタノール30ml溶液に5%パラジウム炭素150mgを加え、水素雰囲気下に18時間撹拌した。不溶物を濾過し、濾液を減圧下で留去して標記化合物1.18g(91%)を得た。
【0068】
1H−NMR(CDCl3, δ):0.90(3H, t, J=7Hz), 1.18−1.43(8H, m), 1.51−1.77(4H, m), 1.89−1.97(1H, m), 2.02−2.09(1H, m), 3.03−3.09(1H, m), 3.31−3.39(1H, m), 3.61−3.69(1H, m), 3,90(1H, d, J=6Hz), 7.31(1H, d, J=8Hz)
IR(ν, KBr, cm-1):3344, 2936, 2860, 1650
FAB−Mass(m/z,%):259(M++1, 100), 86(92)
【0069】
実施例1
N−[(2S,3S)−2−ヒドロキシ−1−[N−[(1S,2S)−2−ヒドロキシシクロヘキサン−1−イル]アミノ]−1−オキソ−3− ヘプチル]−1−[N−(モルホリン−4−カルボニル)アミノ]シクロヘキサンカルボキサミドの合成
【化20】
氷冷下、1−[N−(モルホリン−4−カルボニル)アミノ]シクロヘキサンカルボン酸256mg(1mmol)及びトリエチルアミン202mg(2mmol)の無水テトラヒドロフラン10ml溶液にピバロイルクロリド121mg(1mmol)の無水テトラヒドロフラン1ml溶液を加え、同温度で2時間撹拌した。更に反応液を室温に戻して18時間撹拌した。反応液中の不溶物を濾過し、(2S,3S)−N−[(1S,2S)−2−ヒドロキシシクロヘキサン−1−イル]−3−アミノ−2−ヒドロキシヘプタンアミド258mg(1mmol)のクロロホルム80ml溶液に加え、3時間撹拌した。反応液にクロロホルムを追加して10%硫酸水素カリウム水溶液、飽和炭酸水素ナトリウム水溶液次いで飽和食塩水で洗浄後、無水硫酸マグネシウム乾燥して減圧下で溶媒を留去した。残留物をシリカゲルカラムクロマトグラフィーにて精製して標記化合物468mg(94%)を得た。
【0070】
1H−NMR(CDCl3, δ):0.88(3H, t, J=7Hz), 1.17−1.44(11H, m), 1.45−1.58(1H, m), 1.59− 1.77(6H, m), 1.82−1.97(4H, m), 2.01−2.07(2H, m), 3.31−3.44(5H, m), 3.59−3.69(1H, m), 3.72(4H, t, J=5Hz), 3.76(1H, d, J=4Hz), 4.05−4.14(2H, m), 4.75(1H, s), 5.02(1H, d, J=6Hz), 6.56(1H, d, J=8Hz), 7.03(1H, d, J=8Hz)
IR(ν, KBr, cm-1):3380, 2931, 2859, 1675, 1629
FAB−Mass(m/z,%):497(M++1, 55), 211(100)
【0071】
参考例11
N−[(S)−1,2−ジオキソ−1−[N−[(S)−2−オキソシクロヘキシル]アミノ]−3−ヘプチル]−1−[N−(モルホリン−4−カルボニル)アミノ]シクロヘキサンカルボキサミドの合成
【化21】
窒素気流下、0℃でN,N−ジイソプロピルエチルアミン1.45g (11.2mmol)を三酸化イオウピリジン錯塩1.78g(11.2mmol)の無水ジメチルスルホキシド(5ml)及び無水塩化メチレン(5ml)溶液 に滴下した。さらに、N−[(2S,3S)−2−ヒドロキシ−1−[N−[(1S,2S)−2−ヒドロキシシクロヘキサン−1−イル]アミノ]−1−オキソ−3− ヘプチル]−1−[N−(モルホリン−4−カルボニル)アミノ]シクロヘキサンカルボキサミド 465mg (0.94mmol)の無水塩化メチレン(5ml)溶液を加え、0℃で3時間撹拌した。反応終了後、反応溶液に氷水を加え酢酸エチルで抽出した。有機層を10%クエン酸水溶液、飽和炭酸水素ナトリウム水溶液及び飽和食塩水で順次洗浄し無水硫酸マグネシウムで乾燥後減圧濃縮した。残留物を中性シリカゲルカラムクロマトグラフィーにて精製し、標記化合物402mg(87%)を得た。
【0072】
1H−NMR(CDCl3, δ):0.88(3H, t, J=7Hz), 1.23−1.46(8H,m ), 1.56−2.00(10H, m), 2.03−2.20(3H, m), 2.36−2.70(3H, m), 3.39(4H, t, J=5Hz), 3.72(4H, t, J=5Hz), 4.36−4.47(1H , m), 4.46(1H, s), 5.20−5.25(1H, m), 7.76(1H, d, J=6Hz), 7.93(1H, d, J=7Hz)
IR(ν, KBr, cm-1):3380, 2931, 2859, 1675, 1629
FAB−Mass(m/z, %):493(M++1, 25), 239(54),211(100)
【0073】
参考例12
(2S−trans)−N−[(3,4−メチレンジオキシ)フェニル]−3−ブチルオキシランカルボキサミドの合成
【化22】
氷冷下、(2S−trans)−3−ブチル−オキシランカルボン酸、ジシクロヘキシルアミン塩299mg(1.84mmol)の無水テトラヒドロフラン10ml溶液にピバロイルクロリド222mg(1.84mmol)の無水テトラヒドロフラン2ml溶液を加え、同温度で15分間撹拌した。さらに反応液を室温に戻して2時間撹拌した。反応液中の不溶物を濾過後、氷冷下、3,4−メチレンジオキシアニリン252mg(1.84mmol)の無水テトラヒドロフラン10ml溶液に加え、室温にて2時間撹拌した。減圧下、反応液を濃縮して酢酸エチルを加え、10%硫酸水素カリウム水溶液、飽和炭酸水素ナトリウム水溶液次いで飽和食塩水で洗浄した。有機層を無水硫酸マグネシウムで乾燥後、減圧下で溶媒を留去して標記化合物484mg(100%)を得た。
【0074】
1H−NMR(CDCl3, δ):0.93(3H, t, J=7Hz), 1.22−1.51(4H, m), 1.58−1.80(2H, m), 3.05−3.09(1H, m), 3.33(1H, d, J=2Hz), 5.95(2H, s), 6.74(1H, d, J=8Hz), 6.81(1H, dd, J=8Hz, 2Hz), 7.25(1H, d, J=2Hz), 7.72(1H, s)
IR(ν, NaCl, cm-1):2932, 2872, 1674
【0075】
参考例13
(2S,3S)−N−[(3,4−メチレンジオキシ)フェニル]−3−アジド−2−ヒドロキシヘプタンアミドの合成
【化23】
(2S−trans)−N−[(3,4−メチレンジオキシ)フェニル]−3−ブチルオキシランカルボキサミド484mg(1.84mmol)、アジ化ナトリウム239mg(3.68mmol)及び無水硫酸マグネシウム228mg(1.89mmol)のメタノール 30ml懸濁液を5時間加熱還流した。反応液を室温に戻した後、減圧下反応液を濃縮して酢酸エチルを加え、水次いで飽和食塩水で洗浄した。有機層を無水硫酸マグネシウムで乾燥後、減圧下で溶媒を留去した。残査をシリカゲルカラムクロマトグラフィーで精製し標記化合物395mg(70%)を得た。
【0076】
1H−NMR(CDCl3, δ):0.91(3H, t, J=7Hz), 1.30−1.41(2H, m), 1.42−1.80(4H, m), 3.04(1H, brs), 3.82−3.85(1H, m), 4.40(1H, d, J=4Hz), 5.96(2H, s), 6.76(1H, d, J=8Hz), 6.86(1H, dd, J=8Hz, 2Hz), 7.27(1H, d, J=2Hz), 8.32(1H, s)IR(ν, NaCl, cm-1):2932, 2872, 2104, 1658
【0077】
参考例14
(2S,3S)−N−[(3,4−メチレンジオキシ)フェニル]−3−アミノ−2−ヒドロキシヘプタンアミドの合成
【化24】
(2S,3S)−N−[(3,4−メチレンジオキシ)フェニル]−3−アジド−2−ヒドロキシヘプタンアミド395mg(1.29mmol)のメタノール30ml溶液に5%パラジウム炭素40mgを加え、水素雰囲気下に18時間撹拌した。不溶物を濾過し、濾液を減圧下で留去して標記化合物344mg(95%)を得た。
【0078】
1H−NMR(CDCl3, δ):0.91(3H, t, J=7Hz), 1.20−1.75(6H, m), 3.10(1H, brs), 3.92(1H, d, J=6Hz), 5.95(1H, d, J=6Hz), 5.95(2H, s), 6.76(1H, d, J=8Hz), 6.86(1H, dd, J=8Hz, 2Hz), 7.28(1H, d, J=2Hz), 9.81(1H, s)
IR(ν, KBr, cm-1):3384, 2956, 2872, 1658
【0079】
実施例2
N−[(2S,3S)−2−ヒドロキシ−1−[N−[(3,4−メチレンジオキシ)フェニル]アミノ]−1−オキソ−3−ヘプチル]−1−[N−(モルホリン−4−カルボニル)アミノ]シクロヘキサンカルボキサミドの合成
【化25】
(2S,3S)−N−[(3,4−メチレンジオキシ)フェニル]−3−アミノ−2−ヒドロキシヘプタンアミド344mg(1.23mmol)、1−[N−(モルホリン−4−カルボニル)アミノ]シクロヘキサンカルボン酸315mg(1.23mmol)及び1−ヒドロキシベンゾトリアゾール233(1.48mmol)を無水塩化メチレンに溶解し、続いて窒素気流下、0℃で1−エチル−3−(3−ジメチルアミノプロピル)カルボジイミド284mg(1.48mmol)を加えた。その後、反応液を室温に戻し一晩撹拌した。反応溶液を減圧濃縮し、残留物を酢酸エチル80mlに溶かして、水、10%硫酸水素カリウム水溶液、飽和炭酸水素ナトリウム水溶液及び飽和食塩水で順次洗浄し、無水硫酸マグネシウムで乾燥後減圧濃縮した。残留物をシリカゲルカラムクロマトグラフィーで精製し目的物を574mg(90%)を得た。
【0080】
1H−NMR(CDCl3, δ):0.88(3H, t, J=7Hz), 1.24−1.42(6H, m), 1.52−1.72(10H, m), 1.80−2.10(4H, m), 3.32(4H, t, J=5Hz), 3.67(4H, t, J=5Hz), 4.19−4.22(1H, m), 4.41−4.43(1H, m), 4.64(1H, s), 5.50(1H, d, J=6Hz), 5.94(2H, s), 6.70(1H, d, J=8Hz), 6.89(1H, dd, J=8Hz, 2Hz), 7.33(1H, d, J=2Hz), 8.69(1H, s)
IR(ν, KBr, cm-1):3384, 2932, 2860, 1658
【0081】
参考例15
N−[(S)−1,2−ジオキソ−1−[N−[(3,4−メチレンジオキシ)フェニル]アミノ]−1−オキソ−3−ヘプチル]−1−[N−(モルホリン−4−カルボニル)アミノ]シクロヘキサンカルボキサミドの合成
【化26】
窒素気流下、0℃でN,N−ジイソプロピルエチルアミン861mg (6.66mmol)を三酸化イオウピリジン錯塩1.06g(6.66mmol)の無水ジメチルスルホキシド(5ml)及び無水塩化メチレン(5ml)溶液 に滴下した。さらに、 N−[(2S,3S)−2−ヒドロキシ−1−[N−(3,4−メチレンジオキシフェニル−1−イル)アミノ]−1−オキソ−3−ヘプチル]−1−[N−(モルホリン−4−カルボニル)アミノ]シクロヘキサンカルボキサミド 574mg (1.11mmol)の無水塩化メチレン(5ml)溶液を加え、0℃で3時間撹拌した。反応終了後、反応溶液に氷水を加え酢酸エチルで抽出した。有機層を10%クエン酸水溶液、飽和炭酸水素ナトリウム水溶液及び飽和食塩水で順次洗浄し無水硫酸マグネシウムで乾燥後減圧濃縮した。残留物を中性シリカゲルカラムクロマトグラフィーにて精製し、標記化合物499mg(87%)を得た。
【0082】
1H−NMR(CDCl3, δ):0.89(3H, t, J=7Hz), 1.28−1.42(7H, m), 1.58−1.72(4H, m), 1.85−2.17(5H, m), 3.37(4H, t, J=5Hz), 3.71(4H, t, J=5Hz), 4.43(1H, s), 5.20−5.26(1H, m), 5.97(2H, s), 6.77(1H, d, J=8Hz), 6.95(1H, dd, J=8Hz, 2Hz), 7.35(1H, d, J=2Hz), 8.06(1H, d, J=7Hz), 8.56(1H, s)
IR(ν, KBr, cm-1):2928, 2860, 1666
【0083】
参考例16
(2S−trans)−N−ブチル−3−ブチルオキシランカルボキサミドの合成
【化27】
氷冷下、(2S−trans)−3−ブチル−オキシランカルボン酸、ジシクロヘキシルアミン塩299mg(1.84mmol)の無水テトラヒドロフラン10ml溶液にピバロイルクロリド222mg(1.84mmol)の無水テトラヒドロフラン2ml溶液を加え、同温度で15分間撹拌した。さらに反応液を室温に戻して2時間撹拌した。反応液中の不溶物を濾過後、氷冷下、n−ブチルアミン135mg(1.84mmol)の無水テトラヒドロフラン10ml溶液に加え、室温にて2時間撹拌した。減圧下、反応液を濃縮して酢酸エチルを加え、10%硫酸水素カリウム水溶液、飽和炭酸水素ナトリウム水溶液次いで飽和食塩水で洗浄した。有機層を無水硫酸マグネシウムで乾燥後、減圧下で溶媒を留去して標記化合物366mg(100%)を得た。
【0084】
1H−NMR(CDCl3, δ):0.93(3H, t, J=7Hz), 0.94(3H, t, J=7Hz), 1.26−1.70(10H, m), 2.89−2.93(1H, m), 3.17−3.25(3H, m), 6.10(1H, s)
IR(ν, NaCl, cm-1):2932, 2872, 1662
【0085】
参考例17
(2S,3S)−N−ブチル−3−アジド−2−ヒドロキシヘプタンアミドの合成
【化28】
(2S−trans)−N−ブチル−3−ブチルオキシランカルボキサミド366mg(1.84mmol)、アジ化ナトリウム239mg(3.68mmol)及び無水硫酸マグネシウム228mg(1.89mmol)のメタノール 30ml懸濁液を5時間加熱還流した。反応液を室温に戻した後、減圧下反応液を濃縮して酢酸エチルを加え、水次いで飽和食塩水で洗浄した。有機層を無水硫酸マグネシウムで乾燥後、減圧下で溶媒を留去した。残査をシリカゲルカラムクロマトグラフィーで精製し標記化合物304mg(68%)を得た。
【0086】
1H−NMR(CDCl3, δ):0.93(3H, t, J=7Hz), 0.95(3H, t, J=7Hz), 1.20−1.70(10H, m), 2.86(1H, d, J=4Hz), 3.25−3.35(2H, m), 3.68−3.72(1H, m), 4.21(1H, t, J=4Hz), 6.54(1H, brs)
IR(ν, NaCl, cm-1):2960, 2872, 2100, 1648
【0087】
参考例18
(2S,3S)−N−ブチル−3−アミノ−2−ヒドロキシヘプタンアミドの合成
【化29】
(2S,3S)−N−ブチル−3−アジド−2−ヒドロキシヘプタンアミド304mg(1.25mmol)のメタノール30ml溶液に5%パラジウム炭素30mgを加え、水素雰囲気下に18時間撹拌した。不溶物を濾過し、濾液を減圧下で留去して標記化合物254mg(94%)を得た。
【0088】
1H−NMR(CDCl3, δ):0.91(3H, t, J=7Hz), 0.93(3H, t, J=7Hz), 1.18−1.80(10H, m), 3.01−3.50(1H, m), 3.23−3.29(3H, m), 3.83(1H, d, J=5Hz), 7.45(1H, brs)
IR(ν, KBr, cm-1):3320, 2932, 2860, 1642
【0089】
実施例3
N−[(2S,3S)−2−ヒドロキシ−1−[N−(ブチル)−アミノ]−1−オキソ−3−ヘプチル]−1−[N−(モルホリン−4−カルボニル)アミノ]シクロヘキサンカルボキサミドの合成
【化30】
(2S,3S)−N−ブチル−3−アミノ−2−ヒドロキシヘプタンアミド254mg(1.21mmol)、1−[N−(モルホリン−4−カルボニル)アミノ]シクロヘキサンカルボン酸310mg(1.21mmol)及び1−ヒドロキシベンゾトリアゾール230(1.45mmol)を無水塩化メチレンに溶かし、続いて窒素気流下、0℃で1−エチル−3−(3−ジメチルアミノプロピル)カルボジイミド278mg(1.45mmol)を加えた。その後、反応液を室温に戻し一晩撹拌した。反応溶液を減圧濃縮し、残留物を酢酸エチル80mlに溶かして、水、10%硫酸水素カリウム水溶液、飽和炭酸水素ナトリウム水溶液及び飽和食塩水で順次洗浄し、無水硫酸マグネシウムで乾燥後減圧濃縮した。残留物をシリカゲルカラムクロマトグラフィーで精製し目的物を489mg(89%)を得た。
【0090】
1H−NMR(CDCl3, δ):0.87(3H, t, J=7Hz), 0.94(3H, t, J=7Hz), 1.24−1.41(8H, m), 1.45−1.78(8H, m), 1.84−1.94(2H, m), 1.98−2.05(2H, m), 3.18−3.30(2H, m), 3.70(4H, t, J=5Hz), 3.89(4H, t, J=5Hz), 4.10−4.14(1H, m), 4.26(1H, dd, J=6Hz, 6Hz), 4.65(1H, s), 5.18(1H, d, J=6Hz), 6.73(1H, d, J=8Hz), 6.80(1H, brs)
IR(ν, KBr, cm-1):3368, 2932, 2860, 1650
【0091】
参考例19
N−[(S)−1,2−ジオキソ−1−[N−(ブチル)アミノ]−1−オキソ−3−ヘプチル]−1−[N−[(モルホリン−4−カルボニル)アミノ]シクロヘキサンカルボキサミドの合成
【化31】
窒素気流下、0℃でN,N−ジイソプロピルエチルアミン838mg (6.48mmol)を三酸化イオウピリジン錯塩1.03g(6.48mmol)の無水ジメチルスルホキシド(5ml)及び無水塩化メチレン(5ml)溶液 に滴下した。さらに、N−[(2S,3S)−2−ヒドロキシ−1−[N−(ブチル)−アミノ]−1−オキソ−3−ヘプチル]−1−[N−(モルホリン−4−カルボニル)アミノ]シクロヘキサンカルボキサミド489mg (1.08mmol)の無水塩化メチレン(5ml)溶液を加え、0℃で3時間撹拌した。反応終了後、反応溶液に氷水を加え酢酸エチルで抽出した。有機層を10%クエン酸水溶液、飽和炭酸水素ナトリウム水溶液及び飽和食塩水で順次洗浄し無水硫酸マグネシウムで乾燥後減圧濃縮した。残留物を中性シリカゲルカラムクロマトグラフィーにて精製し、標記化合物415mg(85%)を得た。
【0092】
1H−NMR(CDCl3, δ):0.88(3H, t, J=7Hz), 0.93(3H, t, J=7Hz), 1.22−1.42(9H, m), 1.49−1.70(6H, m), 1.85−2.00(3H, m), 2.06−2.15(2H, m), 3.26−3.38(2H, m), 3.38(4H, t, J=5Hz), 3.72(4H, t, J=5Hz), 4.44(1H, s), 5.17−5.20(1H, m), 6.86(1H, t, J=6Hz), 7.94(1H, d, J=7Hz)
IR(ν, KBr, cm-1):3344, 2932, 2860, 1658
【0093】
参考例20
(2S−trans)−N−[(2S)−1−メトキシ−1−オキソ−3−フェニル−2−プロピル]−3−ブチルオキシランカルボキサミドの合成
【化32】
氷冷下、(2S−trans)−3−ブチル−オキシランカルボン酸、ジシクロヘキシルアミン塩299mg(1.84mmol)の無水テトラヒドロフラン10ml溶液にピバロイルクロリド222mg(1.84mmol)の無水テトラヒドロフラン2ml溶液を加え、同温度で15分間撹拌した。さらに反応液を室温に戻して2時間撹拌した。反応液中の不溶物を濾過後、氷冷下、トリエチルアミン187mg(1.84mmol)を加えた後、L−フェニルアラニン メチルエステル塩酸塩397mg(1.84mmol)を添加し、室温にて2時間撹拌した。減圧下、反応液を濃縮して酢酸エチルを加え、10%硫酸水素カリウム水溶液、飽和炭酸水素ナトリウム水溶液次いで飽和食塩水で洗浄した。有機層を無水硫酸マグネシウムで乾燥後、減圧下で溶媒を留去して標記化合物558mg(100%)を得た。
【0094】
1H−NMR(CDCl3, δ):0.91(3H, t, J=7Hz), 1.20−1.45(4H, m), 1.46−1.63(2H, m), 2.58−2.61(1H, m), 3.01(1H, dd, J=14Hz, 7Hz), 3.16(1H, d, J=2Hz), 3.20(1H, dd, J=14Hz, 7Hz), 3.74(3H, s), 4.81−4.87(1H, m), 6.48(1H, d, J=8Hz),7.05−7.10(2H, m), 7.24−7.31(3H, m)
IR(ν, NaCl, cm-1):2960, 2868, 1684
【0095】
参考例21
(2S,3S)−N−[(2S)−1−メトキシ−1−オキソ−3−フェニル−2−プロピル]−3−アジド−2−ヒドロキシヘプタンアミドの合成
【化33】
(2S)−trans−N−[(2S)−1−メトキシ−1−オキソ−3−フェニル−2−イル]−3−ブチルオキシランカルボキサミド558mg(1.84mmol)、アジ化ナトリウム239mg(3.68mmol)及び無水硫酸マグネシウム228mg(1.89mmol)のメタノール 30ml懸濁液を5時間加熱還流した。反応液を室温に戻した後、減圧下反応液を濃縮して酢酸エチルを加え、水次いで飽和食塩水で洗浄した。有機層を無水硫酸マグネシウムで乾燥後、減圧下で溶媒を留去した。残査をシリカゲルカラムクロマトグラフィーで精製し標記化合物442mg(69%)を得た。
【0096】
1H−NMR(CDCl3, δ):0.90(3H, t, J=7Hz), 1.21−1.62(6H, m), 2.87(1H, d, J=4Hz), 3.09(1H, dd, J=14Hz, 7Hz), 3.16(1H, dd, J=14Hz, 7Hz),3.59−3.63(1H, m), 3.75(3H, s), 4.20(1H, dd,J=4Hz, 4Hz), 4.88−4.93(1H, m), 7.00(1H, d, J=8Hz), 7.14(2H, d, J=8Hz), 7.25−7.33(3H, m)
IR(ν, KBr, cm-1):2856, 2100, 1658
【0097】
参考例22
(2S,3S)−N−[(2S)−1−メトキシ−1−オキソ−3−フェニル−2−プロピル]−3−アミノ−2−ヒドロキシヘプタンアミドの合成
【化34】
(2S,3S)−N−[(2S)−1−メトキシ−1−オキソ−3−フェニル−2−プロピル]−3−アジド−2−ヒドロキシヘプタンアミド442mg(1.27mmol)のメタノール30ml溶液に5%パラジウム炭素45mgを加え、水素雰囲気下に18時間撹拌した。不溶物を濾過し、濾液を減圧下で留去して標記化合物385mg(94%)を得た。
【0098】
1H−NMR(CDCl3, δ):0.89(3H, t, J=7Hz), 1.18−1.70(6H, m), 2.86−2.91(1H, m), 3.06(1H, dd, J=14Hz, 7Hz), 3.18(1H, dd, 14Hz, 7Hz), 3.73(3H, s), 3.76(1H, d, J=7Hz), 4.86−4.92(1H, m), 7.15(1H, d, J=7Hz), 7.21−7.31(5H, m), 8.15(1H, d, J=8Hz)
IR(ν, KBr, cm-1):3364, 2956, 2860, 1652
【0099】
実施例4
N−[(2S,3S)−2−ヒドロキシ−1−[N−[(2S)−1−メトキシ−1−オキソ−3−フェニル−2−プロピル]アミノ]−1−オキソ−3−ヘプチル]−1−[N−(モルホリン−4−カルボニル)アミノ]シクロヘキサンカルボキサミドの合成
【化35】
(2S,3S)−N−[(2S)−1−メトキシ−1−オキソ−3−フェニル−2−イル]−3−アミノ−2−ヒドロキシヘプタンアミド385mg(1.19mmol)、1−[N−(モルホリン−4−カルボニル)アミノ]シクロヘキサンカルボン酸305mg(1.19mmol)及び1−ヒドロキシベンゾトリアゾール226(1.43mmol)を無水塩化メチレンに溶解し、続いて窒素気流下、0℃で1−エチル−3−(3−ジメチルアミノプロピル)カルボジイミド274mg(1.43mmol)を加えた。その後、反応液を室温に戻し一晩撹拌した。反応溶液を減圧濃縮し、残留物を酢酸エチル80mlに溶かして、水、10%硫酸水素カリウム水溶液、飽和炭酸水素ナトリウム水溶液及び飽和食塩水で順次洗浄し、無水硫酸マグネシウムで乾燥後減圧濃縮した。残留物をシリカゲルカラムクロマトグラフィーで精製し標記化合物を587mg(88%)を得た。
【0100】
1H−NMR(CDCl3, δ):0.86(3H, t, J=7Hz), 1.20−1.70(12H, m), 1.80−1.90(2H, m), 1.92−2.02(2H, m), 3.05−3.17(2H, m), 3.36(4H, t, J=5Hz), 3.69(4H, t, J=5Hz), 3.70(3H, s), 4.09−4.14(1H, m), 4.34(1H, dd, J=6Hz, 6Hz), 4.63(1H, s), 4.80−4.86(1H, m), 5.00(1H, d, J=6Hz), 6.57(1H, d, J=8Hz), 7.14(1H, d, J=8Hz), 7.20−7.30(5H, m)
IR(ν, KBr, cm-1):3392, 2932, 2860, 1658
【0101】
参考例23
N−[(S)−1,2−ジオキソ−1−[N−[(2S)−1−メトキシ−1−オキソ−3−フェニル−2−プロピル]アミノ]−1−オキソ−3−ヘプチル]−1−[N−[(モルホリン−4−カルボニル)アミノ]シクロヘキサンカルボキサミドの合成
【化36】
窒素気流下、0℃でN,N−ジイソプロピルエチルアミン814mg (6.30mmol)を三酸化イオウピリジン錯塩1.00g(6.30mmol)の無水ジメチルスルホキシド(5ml)及び無水塩化メチレン(5ml)溶液 に滴下した。さらに、N−[(2S,3S)−2−ヒドロキシ−1−[N−[(2S)−1−メトキシ−1−オキソ−3−フェニル−2−プロピル]アミノ]−1−オキソ−3−ヘプチル]−1−[N−(モルホリン−4−カルボニル)アミノ]シクロヘキサンカルボキサミド587mg (1.05mmol)の無水塩化メチレン(5ml)溶液を加え、0℃で3時間撹拌した。反応終了後、反応溶液に氷水を加え酢酸エチルで抽出した。有機層を10%クエン酸水溶液、飽和炭酸水素ナトリウム水溶液及び飽和食塩水で順次洗浄し無水硫酸マグネシウムで乾燥後減圧濃縮した。残留物を中性シリカゲルカラムクロマトグラフィーにて精製し、標記化合物487mg(83%)を得た。
【0102】
1H−NMR(CDCl3, δ):0.87(3H, t, J=7Hz), 1.20−1.42(7H, m), 1.54−1.76(4H, m), 1.80−1.96(3H, m), 2.05−2.18(2H, m), 3.06−3.18(2H, m), 3.36(4H, t, J=5Hz), 3.71(4H, t, J=5Hz), 3.72(3H, s), 4.46(1H, d, J=6Hz), 4.80−4.85(1H, m), 5.17−5.19(1H, m), 7.09(1H, d, J=8Hz), 7.12(1H, dd, J=8Hz, 2Hz), 7.23−7.31(4H, m), 7.96(1H, d, J=7Hz)
IR(ν, KBr, cm-1):2932, 2860, 1678
【0103】
実施例5
(2S)−N−[(2S,3S)−2−ヒドロキシ−1−[N−[(1S,2S)−2−ヒドロキシシクロヘキサン−1−イル]アミノ]−1−オキソ−3− ヘプチル]−2−(2−メチルカルボニルオキシ)−3−フェニルプロピルアミドの合成
【化37】
(S)−[2−アセチルオキシ−3−フェニル]プロパン酸1.0g(5.5mmol)、(2S,3S)−N−[(1S,2S)−2−ヒドロキシシクロヘキサン−1−イル]−3−アミノ−2−ヒドロキシヘプタンアミド 1.4g(5.5mmol)及び1−ヒドロキシベンゾトリアゾール1.0g(6.6mmol)を塩化メチレン20mlに溶かし、氷冷下1−エチル−3−(3−ジメチルアミノプロピル)カルボジイミド1.3g(6.6mmol)を加えて18時間撹拌した。減圧下で溶媒を留去し残留物に酢酸エチルを加え、10%硫酸水素カリウム水溶液、飽和炭酸水素ナトリウム水溶液次いで飽和食塩水で洗浄後、無水硫酸マグネシウム乾燥して減圧下で溶媒を留去した。残留物をシリカゲルカラムクロマトグラフィーにて精製して標記化合物2.2g(84%)を得た。
【0104】
1H−NMR(CDCl3, δ):0.84(3H, t, J=7Hz), 0.99−1.37(8H, m), 1.43−1.58(2H, m), 1.68−1.74(2H, m), 2.01−2.10(1H, m), 2.07(3H, s), 3.10(1H, dd, J=14Hz, 7Hz), 3.17(1H, dd, J=14Hz, 6Hz), 3.38(1H, dt, J=10Hz, 4Hz), 3.55−3.62(1H, m), 3.97−4.03(1H, m), 4.16(1H, s), 4.97(1H, brs ), 5.24(1H, dd, J=7Hz, 6Hz), 6.35(1H, d, J=8Hz), 6.93(1H, d, J=8Hz), 7.18−7.31(5H, m)
IR(ν, KBr, cm-1):3314, 2935, 1671, 1636
【0105】
参考例24
(2S)−N−[(S)−1,2−ジオキソ−1−[N−[(S)−2−オキソシクロヘキシル]アミノ]−3−ヘプチル]−2−(アセチルオキシ)−3−フェニルプロピルアミドの合成
【化38】
窒素気流下、0℃でN,N−ジイソプロピルエチルアミン700mg (5.4mmol)を三酸化イオウピリジン錯塩854mg(5.4mmol)の無水ジメチルスルホキシド(20ml)及び無水塩化メチレン(15ml)溶液 に滴下した。さらに、(2S)−N−[(2S,3S)−2−ヒドロキシ−1−[N−[(1S,2S)−2−ヒドロキシシクロヘキサン−1−イル]アミノ]−1−オキソ−3− ヘプチル]−2−(アセチルオキシ)−3−フェニルプロピルアミド200mg (0.45mmol)の無水塩化メチレン(5ml)溶液を加え、0℃で3時間撹拌した。反応終了後、反応溶液に氷水を加え酢酸エチルで抽出した。有機層を10%クエン酸水溶液、飽和炭酸水素ナトリウム水溶液及び飽和食塩水で順次洗浄し無水硫酸マグネシウムで乾燥後減圧濃縮した。残留物をエーテル洗浄し、標記化合物115mg(58%)を得た。
【0106】
1H−NMR(CDCl3, δ):0.85(3H, t, J=7Hz), 1.10−1.94(10H, m), 2.10(3H, s), 2.15−2.20(1H, m), 2.43(1H, dt, J=13Hz,6Hz), 2.56−2.68(2H, m), 3.07(1H, dd, J=14Hz, 7Hz), 3.32(1H, dd, J=14Hz, 5Hz), 4.38−4.44(1H, m), 5.26(1H, dt,J=8Hz, 5Hz), 5.39(1H, dd, J=7Hz, 5Hz), 6.55(1H, d, J=8Hz ), 7.16−7.29(5H, m ), 7.75(1H, d, J=6Hz )
IR(ν, KBr, cm-1):3334, 2934, 2862, 1740, 1671
【0107】
実施例6
(2S)−N−[(2S,3S)−2−ヒドロキシ−1−[N−[(1S,2S)−2−ヒドロキシシクロヘキサン−1−イル]アミノ]−1−オキソ−3−ヘプチル]−4−メチル−2−[N−(フェニルメトキシカルボニル)アミノ]ペンタンアミドの合成
【化39】
アルゴンガス気流下 0℃で L−N−フェニルメトキシカルボニルロイシン761mg(1.1mmol) の無水テトラヒドロフラン 25ml 溶液にピバロイルクロリド 0.23ml(1.9mmol)、次いで (2S,3S)−N−[(1S,2S)−2−ヒドロキシシクロヘキサン−1−イル]−3−アミノ−2−ヒドロキシヘプタンアミド 400mg(1.5mmol) の無水テトラヒドロフラン−クロロホルム (5:3)40ml 懸濁液を滴下し、同温で 2 時間撹拌した。更に反応液を室温に戻して 10 時間撹拌した。反応終了後、反応液に飽和塩化アンモニウム水 30ml を加えテトラヒドロフランとクロロホルムを留去した。残留物を 5%−メタノール/クロロホルム 50ml で 3 回抽出した。有機層を合わせ飽和炭酸水素ナトリウム水溶液 100ml、次いで飽和食塩水 100ml で洗浄し、無水硫酸ナトリウムで乾燥後減圧濃縮した。残留物をエタノール−ジエチルエーテル (5:2)35ml から再結晶し、標記化合物 210mg(26.8%) を得た。
【0108】
1H−NMR (DMSO−d6, δ) : 0.79 (3H, t, J=7Hz), 0.85 (3H, d, J=7Hz), 0.87 (3H, d, J=7Hz), 1.04−1.31 (9H, m), 1.34−1.50 (3H, m), 1.52−1.66 (3H, m), 1.76−1.87 (2H, m), 3.26−3.42 (2H, m), 3.84 (1H, dd, J = 6Hz,3Hz), 4.00−4.13 (2H, m), 4.51 (1H, d, J = 5Hz), 5.02 (2H, s), 5.71 (1H, d, J=6Hz) ,7.28−7.40 (6H , m), 7.43 (1H, d, J=8Hz), 7.47 (1H, d, J=9Hz)
IR(ν, KBr, cm-1):3322, 2937, 1660, 1531
【0109】
参考例25
(2S)−N−[(S)−1,2−ジオキソ−1−[N−[(S)−2−オキソシクロヘキシル]アミノ]−3−ヘプチル]−4−メチル−2−[N−(フェニルメトキシカルボニル)アミノ]ペンタンアミドの合成
【化40】
アルゴンガス気流下 0℃で三酸化イオウピリジン錯塩 567mg(3.6mmol) の無水ジメチルスルホキシド−塩化メチレン (1:1)4ml 溶液にジイソプロピルエチルアミン 0.62ml (3.6mmol)、次いで、(2S)−N−[(2S,3S)−2−ヒドロキシ−1−[N−[(1S,2S)−2−ヒドロキシシクロヘキサン−1−イル]アミノ]−1−オキソ−3−ヘプチル]−4−メチル−2−[N−(フェニルメトキシカルボニル)アミノ]ペンタンアミド 150mg(0.3mmol) の無水ジメチルスルホキシド 2ml 溶液を滴下し、同温で 5 時間撹拌した。反応終了後、反応液に氷水 25ml を加え酢酸エチル 20ml で 3 回抽出した。有機層を合わせ 10%−クエン酸水溶液 50ml、飽和炭酸水素ナトリウム水溶液 50ml、次いで飽和食塩水50ml で洗浄し、無水硫酸ナトリウムで乾燥後減圧濃縮した。残留物を中性シリカゲルカラムクロマトグラフィーに付し、ヘキサン−酢酸エチル (11:9) 溶出液より標記化合物 120mg を得、更に酢酸エチル−ヘキサン (3:2)5ml から再結晶し標記化合物 90mg(60.5%)を得た。
【0110】
1H−NMR(CDCl3, δ):0.87(3H, t, J=7Hz), 0.94(6H, d, J=6Hz), 1.20−1.55(6H, m), 1.58−1.74(4H, m), 1.74−1.87(1H, m), 1.87−2.00(2H, m), 2.12−2.21(1H, m), 2.40(1H, dt, J=14Hz, 6Hz), 2.53−2.61(1H, m),2.61−2.70(1H, m), 4.16−4.25(1H, m), 4.37−4.45(1H, m), 5.08−5.18(3H, m), 5.28(1H, dt, J=8Hz,5Hz), 6.54(1H, d, J=8Hz), 7.29−7.40(5H, m), 7.77(1H, d, J=6Hz)
IR(ν, KBr, cm-1):3320, 1689, 1661, 1526
【0111】
実施例7
(2S)−N−[(2S,3S)−2−ヒドロキシ−1−[N−[(1S,2S)−2−ヒドロキシシクロヘキサン−1−イル]アミノ]−1−オキソ−3−ヘプチル]−1−(フェニルメトキシカルボニル)ピロリジン−2−カルボキサミドの合成
【化41】
L−N−フェニルメトキシカルボニルプロリン 523mg(2.1mmol)、(2S,3S)−N−[(1S,2S)−2−ヒドロキシシクロヘキサン−1−イル]−3−アミノ−2−ヒドロキシヘプタンアミド518mg(2.0mmol)及び 1−ヒドロキシベンゾトリアゾール 338mg (2.2 mmol)をジメチルホルムアミド20mlに溶かし、氷冷下1−エチル−3−(3−ジメチルアミノプロピル)カルボジイミド423mg(2.2mmol)を加えて18時間撹拌した。反応溶液に1N塩酸を加え、クロロホルムで抽出した。有機層を飽和炭酸水素ナトリウム水溶液次いで飽和食塩水で洗浄後、無水硫酸マグネシウム乾燥して減圧下で溶媒を留去した。残留物をシリカゲルカラムクロマトグラフィーにて精製して標記化合物709mg(72%)を得た。
【0112】
1H−NMR(DMSO−d6, δ) : 0.68(1.8H, t, J=7Hz), 0.80(1.2H, t, J=7Hz), 0.94−1.44(10H, m), 1.52−1.64(2H, m), 1.74−1.94(5H, m), 1.97−2.18(1H, m), 3.26−3.49(4H, m), 3.81−3.86 (1H, m), 4.00−4.09(1H, m), 4.23(0.4H, dd, J=8Hz,3Hz), 4.30(0.6H, dd, J=8Hz, 3Hz), 4.50(1H, d,J=5Hz), 4.93−5.11(2H, m), 5.70(0.4H, d, J=5Hz), 5.75(0.6H, d, J=5Hz), 7.24−7.40(6H, m), 7.62(0.4H, d, J=9Hz), 7.70(0.6H, d, J=9Hz)
IR(ν, KBr, cm-1):3401, 2933, 1664, 1637
【0113】
参考例26
(2S)−N−[(S)−1,2−ジオキソ−1−[N−[(S)−2−オキソシクロヘキシル]アミノ]−3−ヘプチル]−1−(フェニルメトキシカルボニル)ピロリジン−2−カルボキサミドの合成
【化42】
アルゴンガス気流下 0°C で三酸化イオウピリジン錯塩 1.38g(8.6mmol) の無水ジメチルスルホキシド−塩化メチレン (1:1)10ml 溶液にジイソプロピルエチルアミン 1.47ml (8.6mmol)、次いで、(2S)−N−[(2S,3S)−2−ヒドロキシ−1−[N−[(1S,2S)−2−ヒドロキシシクロヘキサン−1−イル]アミノ]−1−オキソ−3−ヘプチル]−1−(フェニルメトキシカルボニル)ピロリジン−2−カルボキサミド 350mg(0.7mmol) の無水ジメチルスルホキシド 5ml 溶液を滴下し、同温で 5 時間撹拌した。反応終了後、反応液に氷水 25ml を加え酢酸エチル 30ml で 3 回抽出した。有機層を合わせ 10%−クエン酸水溶液 100ml、飽和炭酸水素ナトリウム水溶液 100ml、次いで飽和食塩水 100ml で洗浄し、無水硫酸ナトリウムで乾燥後減圧濃縮した。残留物を中性シリカゲルカラムクロマトグラフィーにて精製し、標記化合物 300mg(86.1%) を得た。
【0114】
1H−NMR(DMSO−d6, δ):0.77(1.8H, t, J=7Hz), 0.86(1.2H, t, J=7Hz), 1.12−1.58(6H, m), 1.63−1.92(7H, m), 1.96−2.05(1H, m), 2.07−2.24(2H, m), 2.27−2.34(1H, m),2.48−2.58(1H, m), 3.32−3.48(2H, m), 4.28(0.4H, dd, J=9Hz, 3Hz), 4.33(0.6H, dd, J=9Hz,3Hz), 4.39−4.47(1H, m), 4.95(1H, ddd, J= 9Hz, 7Hz,3Hz), 4.99−5.11(2H, m), 7.25−7.40(5H, m), 8.28(0.4H, d, J=7Hz),8.32(0.6H, d, J=7Hz), 8.53(0.4H, d, J=8Hz), 8.55(0.6H, d, J=8Hz)
IR(ν, KBr, cm-1):3320, 2935, 2863, 1704, 1666
【0115】
【発明の効果】
本発明により新規なアミノアルコール誘導体を提供することができ、当該誘導体は、プロテアーゼ阻害活性を有する有用なα−ケトアミド誘導体を、極めて経済的かつ立体選択的に導くことのできる製造中間体として用いることができる。[0001]
BACKGROUND OF THE INVENTION
The present invention provides a general formula
[Chemical 6]
Wherein R 1 and R 2 are the same or different and each represents a substituted or unsubstituted linear, branched or cyclic alkyl group, a substituted or unsubstituted linear, branched or cyclic alkenyl. A group, a substituted or unsubstituted aromatic hydrocarbon group or a substituted or unsubstituted heterocyclic group, and R3 is a substituted or unsubstituted linear, branched or cyclic alkyl group, substituted or unsubstituted. A straight-chain, branched-chain or cyclic alkenyl group, a substituted or unsubstituted aromatic hydrocarbon group, a substituted or unsubstituted heterocyclic group, R6-O- or R7-N (R8)-. Is a substituted or unsubstituted linear, branched or cyclic alkyl group, a substituted or unsubstituted linear, branched or cyclic alkenyl group, a substituted or unsubstituted aromatic hydrocarbon group Or replacement or nothing R7 and R8 are the same or different and each represents a hydrogen atom, a substituted or unsubstituted linear, branched or cyclic alkyl group, a substituted or unsubstituted linear or branched group. A linear or cyclic alkenyl group, a substituted or unsubstituted aromatic hydrocarbon group or a substituted or unsubstituted heterocyclic group, and R4 and R5 may be the same groups as R7 and R8, R4 and R5 may be combined to form a ring, X is —O— or —N (R9) —, and R9 is a hydrogen atom or a substituted or unsubstituted straight chain, branched chain or It is a cyclic alkyl group and can form a ring integrally with R4 or R5.) The amino alcohol derivative represented by the general formula (I) can be used, for example, as an intermediate for producing an α-ketoamide derivative having protease inhibitory activity.
[0002]
[Prior art]
Protease, a proteolytic enzyme, may be involved in the development and development of many diseases such as hypertension, thrombosis, pancreatitis, cancer, Alzheimer, emphysema, neurodegenerative diseases, allergic diseases, muscular dystrophy, rheumatism, osteoporosis, and periodontal diseases. Known (protein nucleic acid enzyme, 42 , No14, (1997), experimental medicine, 17 No. 15, (1999)), and its inhibitory substance, ie, protease inhibitor, is expected as a target for pharmaceuticals.
[0003]
Among these proteases, it is reported that they have inhibitory activity against serine proteases (elastase, tryptase, trypsin, chymotrypsin, prolyl endopeptidase) and cysteine proteases (calpain, cathepsin B, cathepsin L) (Japanese Patent Laid-Open No. 4-149166). JP-A-4-21648, JP-A-6-504547, WO9816512, J. Med. 39 , 4089 (1996), Exp. Opin. Ther. Patents. , 8 , 1707 (1998)) is a compound that is sufficiently expected to exhibit an inhibitory activity against cathepsin K, which has recently been reported to be closely involved in bone metabolism.
[0004]
As a typical method for synthesizing a protease inhibitor having this α-ketoamide structure, (A) J. Med. Chem. , 36 , 3472 (1993) further describes (B) J. Med. Chem. , 37 2918 (1994).
[0005]
[Problems to be solved by the invention]
In the method (A), the target compound α-ketoamide derivative cannot be obtained as an optically active substance, and in the method (B), (1) the optically active amino acid as a starting material is expensive, 2) Since amino acids are used as starting materials, only limited substituents can be introduced into R1, and (3) the α-hydroxyl of the reaction precursor cannot be stereoselectively constructed, resulting in a diastereomeric mixture. It is difficult to achieve sufficient purification, and it is not satisfactory for use as an industrial production method.
[0006]
[Means for Solving the Problems]
As a result of intensive investigations to overcome the conventional drawbacks, the present inventors have found that the substituent of R1 is not limited to the amino acid structure, and a raw material for producing an α-ketoamide derivative stereoselectively (see above). The present invention was completed by finding an amino alcohol derivative represented by the general formula (I).
[0007]
Hereinafter, in describing the present invention in detail, the alkyl group of R1 to R9 may be any of a linear, branched, or cyclic alkyl group having 1 to 12 carbon atoms. Group, n-propyl group, 1-methylethyl group, cyclopropyl group, n-butyl group, 2-methylpropyl group, 1-methylpropyl group, 1,1-dimethylethyl group, cyclobutyl group, n-pentyl group, 3-methylbutyl group, cyclopentyl group, 2,2-dimethylpropyl group, 1-methylcyclobutyl group, cyclobutylmethyl group, n-hexyl group, 4-methylpentyl group, cyclohexyl group, 1-methylcyclopentyl group, cyclopentylmethyl Group, (1-methylcyclobutyl) methyl group, n-heptyl group, 5-methylhexyl group, 4,4-dimethylpentyl group, Loheptyl group, cyclohexylmethyl group, (1-methylcyclopentyl) methyl group, n-octyl group, 6-methylheptyl group, 5,5-dimethylhexyl group, (1-methylcyclohexyl) methyl group, n-nonyl group, 7 -Methyloctyl group, 6,6-dimethylheptyl group, n-decyl group, 8-methylnonyl group, 7,7-dimethyloctyl group, n-indecyl group, 9-methyldecyl group, 8,8-dimethylnonyl group, n -Dodecacil group, 10-methylundecayl group, 9,9-dimethyldecacil group and the like can be mentioned.
[0008]
The substituted or unsubstituted alkenyl group represented by R1 to R8 may be any of a straight chain, branched chain or cyclic alkenyl group having 2 to 6 carbon atoms, such as a 1-methyl-1-propenyl group. 1-methyl-2-propenyl group, 2-methyl-2-propenyl group, ethenyl group, 1-methylethenyl group, 1-propenyl group, 2-propenyl group, 1-butenyl group, 2-butenyl group, 2-pentenyl Groups, 1-pentenyl group, 1,3-butanedienyl group, 1-hexenyl group, 2-hexenyl group, 1,3-pentadienyl group, 1,3-hexadienyl group and the like. Examples of the substituent of the alkenyl group include a substituted or unsubstituted aromatic hydrocarbon group and a substituted or unsubstituted heterocyclic group.
[0009]
The substituted or unsubstituted aromatic hydrocarbon group represented by R1 to R8 is monocyclic or polycyclic, and may further have one or more various substituents on the ring. For example, phenyl group, 4-methylphenyl group, 3,4-dimethylphenyl group, 4-methoxyphenyl group, 2,3-dimethoxyphenyl group, 3,4-dimethoxyphenyl group, 3,5-dimethoxyphenyl Group, 2,3-methylenedioxyphenyl group, 3,4-methylenedioxyphenyl group, 4-nitrophenyl group, 3,4-dinitrophenyl group, 4-chlorophenyl group, 3,4-dichlorophenyl group, 4- Bromophenyl group, 3,4-dibromophenyl group, 4-iodophenyl group, 4-fluorophenyl group, 2,3-difluorophenyl group, 3,4-difluorophenyl group, 3, -Difluorophenyl group, 4-trifluoromethylphenyl group, 3-phenoxyphenyl group, 4-phenoxyphenyl group, 4- (1-naphthoxy) phenyl group, 4-acetaminophenyl group, 1-naphthyl group, 2-naphthyl Groups and the like.
[0010]
The substituted or unsubstituted heterocyclic group represented by R1 to R8 is a 5-membered or 6-membered ring group containing at least one hetero atom such as a nitrogen atom, a sulfur atom, or an oxygen atom as a ring constituent atom. It may be condensed with a ring, for example, 2-pyridyl group, 2-furyl group, 2-thienyl group, 2-indolyl group, 2-quinolyl group, 3-isoquinolyl group, 2-benzofuranyl group, 2-benzothienyl. Group, 2-imidazolyl group, 2-benzimidazolyl group, 2-thiazolyl group, 2-oxazolyl group, 2-pyrazolyl group, 2-pyrimidyl group, 2-pyrimidinyl group, 2-dioxanyl group, 2-thiazolidinyl group, 2- Imidazolidinyl group, 2-oxotetrahydrofuran-3-yl group, 2-benzothiazolyl group, 2-quinazoline group, hexahydro-2-azenopin-3-yl , Morpholino group, and thiamorpholino group, pyrrolidino group, piperidino group, piperazino group, perhydro-4-azepin-1-yl group, a perhydro-4 Azaazepin-1-yl group. The heterocyclic ring may have one or more substituents. Examples of the substituent include acetyl group, methoxycarbonyl group, ethoxycarbonyl group, 2-methyl-2-propyloxycarbonyl group, methyl A sulfonyl group, a methoxy group, a benzoyl group, etc. can be mentioned.
[0011]
Examples of the substituent on the alkyl group include a hydroxyl group, an oxo group, a halogen atom, a substituted or unsubstituted C2-C6 linear, branched or cyclic alkenyl group, substituted or unsubstituted. Aromatic hydrocarbon group, substituted or unsubstituted heterocyclic group, nitro group, substituted or unsubstituted amino group, substituted or unsubstituted sulfonyl group, substituted or unsubstituted alkoxyl group, substituted or unsubstituted alkylthio group Substituted or unsubstituted aryloxy groups, substituted or unsubstituted arylthio groups, acyl groups, substituted or unsubstituted alkoxycarbonyl groups, substituted carbamoyl groups, substituted sulfonamido groups, substituted amide groups, mercapto groups, cyano groups, etc. Can be mentioned.
[0012]
Here, the alkenyl group mentioned as a substituent to the alkyl group of R1-R8 can mention the same group as the above-mentioned alkenyl group.
[0013]
Moreover, the substituted or unsubstituted aromatic hydrocarbon group which is a substituent to the alkyl group or alkenyl group of R1 to R8 can be the same group as the above-described aromatic hydrocarbon group.
[0014]
Examples of the substituted or unsubstituted heterocyclic group which is a substituent to the alkyl group or alkenyl group of R1 to R8 can include the same groups as those described above.
[0015]
The substituted amino group, which is a substituent to the alkyl group of R1 to R8, refers to a secondary amino group or a tertiary amino group substituted with various substituents. Examples thereof include the same groups as the substituted or unsubstituted alkyl group, the substituted or unsubstituted alkenyl group, the substituted or unsubstituted aromatic hydrocarbon group, and the substituted or unsubstituted heterocyclic group.
[0016]
Examples of the substituted sulfonyl group that is a substituent to the alkyl group of R1 to R8 include a methylsulfonyl group, an n-butylsulfonyl group, a 2,2-dimethylethylsulfonyl group, a cyclohexylsulfonyl group, a phenylsulfonyl group, 4- Methylphenylsulfonyl group, 4-fluorophenylsulfonyl group, 4-chlorophenylsulfonyl group, 4-nitrophenylsulfonyl group, 2-naphthylsulfonyl group, 3,4-dimethoxyphenylsulfonyl group, 3,4-methylenedioxyphenylsulfonyl group 2-pyridylsulfonyl group, 2-furylsulfonyl group, 2-thienylsulfonyl group, 2-quinolylsulfonyl group, 3-isoquinolylsulfonyl group, phenylmethylsulfonyl group, 4-fluorophenylmethylsulfonyl group, 4-chlorophenyl Mechi A sulfonyl group, 4-nitrophenyl methylsulfonyl group, 2-naphthyl methylsulfonyl group, 3,4-dimethoxyphenyl methylsulfonyl group, and a 3,4-methylenedioxyphenyl methylsulfonyl group.
[0017]
The alkoxy group, which is a substituent to the alkyl group of R1 to R8, is an alkyl-substituted oxy group having 1 to 6 carbon atoms as described above. For example, a methoxy group, an ethoxy group, an n-propoxy group, 1- Methylethyloxy group, n-butoxy group, 2-methylpropyloxy group, 1-methylpropyloxy group, 2-methyl-2-propyloxy group, 2,2-dimethylethyloxy group, n-pentyloxy group, 3 -Methylbutyloxy group, n-hexyloxy group, 4-methylpentyloxy group, cyclohexyloxy group and the like can be mentioned. Examples of the substituent for the alkoxyl group include the same groups as the substituents for the aforementioned alkenyl group.
[0018]
The alkylthio group, which is a substituent to the alkyl group of R1 to R8, is an alkyl-substituted thio group having 1 to 6 carbon atoms as described above, such as methylthio group, ethylthio group, n-propylthio group, 1 -Methylethylthio group, n-butylthio group, 2-methylpropylthio group, 1-methylpropylthio group, 2-methyl-2-propylthio group, 2,2-dimethylethylthio group, n-pentylthio group, 3- Examples thereof include a methylbutylthio group, an n-hexylthio group, a 4-methylpentylthio group, a cyclohexylthio group, and the like. Furthermore, examples of the substituent for the alkylthio group include the same groups as the substituents for the alkenyl group described above.
[0019]
Examples of the substituted or unsubstituted aryloxy group which is a substituent to the alkyl group of R1 to R8 include a phenyloxy group, a 4-methylphenyloxy group, a 4-fluorophenyloxy group, a 4-chlorophenyloxy group, 4 -Nitrophenyloxy group, 2-naphthyloxy group, 3,4-dimethoxyphenyloxy group, 3,4-methylenedioxyphenyloxy group, 2-pyridyloxy group, 2-furyloxy group, 2-thienyloxy group, 2-quinolyloxy group, 3-isoquinolyloxy group, 4-nitrophenylmethyloxy group, 2-naphthylmethyloxy group, 3,4-dimethoxyphenyloxy group, 3,4-methylenedioxyphenylmethyloxy group, etc. Can be mentioned.
[0020]
Examples of the substituted or unsubstituted arylthio group which is a substituent to the alkyl group of R1 to R8 include a phenylthio group, a 4-methylphenylthio group, a 4-fluorophenylthio group, a 4-chlorophenylthio group, and 4-nitro. Phenylthio group, 2-naphthylthio group, 3,4-dimethoxyphenylthio group, 3,4-methylenedioxyphenylthio group, 2-pyridylthio group, 2-furylthio group, 2-thienylthio group, 2-quinolylthio group, 3 -Isoquinolylthio group, phenylmethylthio group, 4-fluorophenylmethylthio group, 4-chlorophenylmethylthio group, 4-nitrophenylmethylthio group, 2-naphthylmethylthio group, 3,4-dimethoxyphenylmethylthio group, 3,4-methylenedioxy Examples thereof include a phenylmethylthio group.
[0021]
The substituted or unsubstituted alkoxycarbonyl group which is a substituent to the alkyl group of R1 to R8 is, for example, a methoxycarbonyl group, an ethoxycarbonyl group, an n-propoxycarbonyl group, an n-butoxycarbonyl group, or 2,2-dimethylethyl. Examples thereof include an oxycarbonyl group, a cyclohexyloxycarbonyl group, and a phenylmethyloxycarbonyl group.
[0022]
The substituted carbamoyl group, which is a substituent to the alkyl group of R1 to R8, refers to a group represented by R3—NHCO— in which various substituents are bonded to the nitrogen atom of the carbamoyl bond group, where the bond is bonded to the nitrogen atom. Examples of the substituent R3 include the above-described substituted or unsubstituted alkyl group, substituted or unsubstituted alkenyl group, substituted or unsubstituted aromatic hydrocarbon group, substituted or unsubstituted heterocyclic group, substituted or unsubstituted amino Groups such as N-methylcarbamoyl group, N, N-dimethylcarbamoyl group, N-butylcarbamoyl group, N, N-dibutylcarbamoyl group, N- (2,2-dimethylethyl) carbamoyl group. N-cyclohexylcarbamoyl group, N-phenylcarbamoyl group, N- (4-methylphenyl) carbamoyl group, N- (4-fluorophenyl) carba Moyl group, N- (4-chlorophenyl) carbamoyl group, N- (4-nitrophenyl) carbamoyl group, N, N-diphenylcarbamoyl group, N-naphthylcarbamoyl group, N- (3,4-dimethoxyphenyl) carbamoyl group N- (3,4-methylenedioxyphenyl) carbamoyl group, N-methyl-N-phenylcarbamoyl group, N-methyl-N-naphthylcarbamoyl group, N- (2-pyridyl) carbamoyl group, N- (2 -Furyl) carbamoyl group, N- (2-thienyl) carbamoyl group, N- (2-quinolyl) carbamoyl group, N- (3-isoquinolyl) carbamoyl group, N- (phenylmethyl) carbamoyl group, N- (4- Fluorophenylmethyl) carbamoyl group, N- (4-chlorophenylmethyl) carbamoyl group, N- ( -Nitrophenylmethyl) carbamoyl group, N- (naphthylmethyl) carbamoyl group, N- (3,4-dimethoxyphenylmethyl) carbamoyl group, N- (3,4-methylenedioxyphenylmethyl) carbamoyl group, etc. Can do.
[0023]
The substituted sulfonamide group, which is a substituent to the alkyl group of R1 to R8, refers to a group represented by R4-SO2NH- in which various substituents are bonded to the sulfur atom of the sulfonamide bonding group, where sulfur As the substituent R4 bonded to the atom, the above-mentioned substituted or unsubstituted alkyl group, substituted or unsubstituted alkenyl group, substituted or unsubstituted aromatic hydrocarbon group, substituted or unsubstituted heterocyclic group, substituted or unsubstituted Examples include substituted amino groups.
[0024]
The substituted amide group, which is a substituent to the alkyl group of R1 to R8, refers to a group represented by R5-CONH- in which various substituents are bonded to the carbon atom of the amide bond group, where the bond is bonded to the carbon atom. Examples of the substituent R5 include a phenoxy group, a 1-naphthyloxy group, a 2-naphthyloxy group, the above-described substituted or unsubstituted alkyl group, a substituted or unsubstituted alkenyl group, and a substituted or unsubstituted aromatic hydrocarbon group. A substituted or unsubstituted heterocyclic group, a substituted or unsubstituted amino group, a substituted or unsubstituted alkoxyl group, and the like.
[0025]
The ring formed by integrating R4 and R5 is a saturated cyclic alkyl group having 5 to 7 carbon atoms or a saturated heterocyclic group having 3 to 6 carbon atoms including a hetero atom. Examples of the saturated cyclic alkyl group having 5 to 7 carbon atoms include groups derived from cyclopentane, cyclohexane, cycloheptane and the like. In addition, the saturated heterocyclic group having 3 to 6 carbon atoms including a hetero atom is derived from, for example, pyrrolidine, piperidine, piperazine, morpholine, perhydroazepine, oxolane, oxane, oxepane, thiolane, thiane, thiepan, etc. Examples of the hetero atom include an oxygen atom, a sulfur atom, and a nitrogen atom. Moreover, the C3-C6 saturated heterocyclic group containing a hetero atom can also be condensed with a benzene ring. These saturated cyclic alkyl group having 5 to 7 carbon atoms and saturated heterocyclic group having 3 to 6 carbon atoms including a hetero atom may have a substituent, and examples of the substituent include a hydroxyl group, Substituted or unsubstituted heterocycles such as halogen atoms, substituted or unsubstituted alkyl groups, substituted or unsubstituted aromatic hydrocarbon groups such as phenyl groups, methylphenyl groups, and naphthyl groups, thienyl groups, furyl groups, and pyridyl groups Group, nitro group, substituted or unsubstituted amino group, substituted or unsubstituted sulfonyl group, substituted or unsubstituted alkoxyl group, substituted or unsubstituted alkylthio group, substituted or unsubstituted aryloxy group, substituted or unsubstituted And the same groups as those described above, such as arylthio group, acyl group, substituted or unsubstituted alkoxycarbonyl group, substituted carbonyl group, mercapto group, cyano group, and the like. That.
[0026]
The ring formed by integrating R9 and R4 or R5 is a saturated heterocyclic group having 3 to 6 carbon atoms and containing a nitrogen atom. Examples of the saturated heterocyclic group having 3 to 6 carbon atoms including a nitrogen atom include groups derived from pyrrolidine, piperidine, piperazine, morpholine, perhydroazepine and the like, and may be condensed with a benzene ring. it can. The saturated heterocyclic group may have a substituent. Examples of the substituent include a hydroxyl group, a halogen atom, a substituted or unsubstituted alkyl group, a phenyl group, a methylphenyl group, and a naphthyl group. Substituted or unsubstituted heterocyclic group such as unsubstituted aromatic hydrocarbon group, thienyl group, furyl group, pyridyl group, nitro group, substituted or unsubstituted amino group, substituted or unsubstituted sulfonyl group, substituted or unsubstituted Substituted alkoxyl group, substituted or unsubstituted alkylthio group, substituted or unsubstituted aryloxy group, substituted or unsubstituted arylthio group, acyl group, substituted or unsubstituted alkoxycarbonyl group, substituted carbonyl group, mercapto group, cyano Examples thereof include the same groups as those described above.
[0027]
The amino alcohol derivative represented by the general formula (I) can be produced according to the following formula.
[Chemical 7]
(Wherein R1 to R5 are the same as R1 to R5 in the general formula (I)).
[0028]
In this step, the amine derivative represented by the general formula (II) and the carboxylic acid derivative represented by the general formula (III) are condensed to maintain the three-dimensional structure, and the general formula (I) Is a step of producing an amino alcohol derivative represented by the formula:
[0029]
In this step, the carboxylic acid derivative represented by the general formula (III) has a carboxyl group of pivaloyl chloride, isobutyl chlorocarbonate, ethyl chlorocarbonate, p-toluene in the presence of a base such as triethylamine, pyridine, or dimethylaminopyridine. After converting into a mixed acid anhydride using sulfonyl chloride, methanesulfonyl chloride, or the like, it can be condensed with an amine derivative represented by the general formula (II). The reaction is preferably carried out in an inert solvent, such as halogenated hydrocarbons such as dichloromethane, chloroform and dichloroethane, aromatic hydrocarbons such as benzene, toluene and xylene, diethyl ether, dimethoxyethane, tetrahydrofuran and dioxane. Ethers, dimethylformamide, acetonitrile, ethyl acetate and the like can be used alone or in combination. The reaction temperature can be carried out at -20 ° C to 40 ° C.
The reaction between the carboxylic acid derivative (III) and the amine derivative (II) can be carried out in the presence of a condensing agent. Examples of the condensing agent include dicyclohexylcarbodiimide, 1-ethyl-3- (3-dimethylaminopropyl). ) A carbodiimide reagent such as carbodiimide and isopropylcarbodiimide can be used.
Furthermore, this step uses the condensing agent to condense the carboxylic acid derivative (III) with N-hydroxysuccinimide, p-nitrophenol, 1-hydroxybenzotriazole, etc. to give an active ester, and then the amine derivative (II ).
[0030]
This step corresponds to each steric structure of the amine derivatives (IIa to IId), and the amino alcohol derivatives (Ia to Id) shown in the following table can be produced while retaining the steric structure.
[Table 1]
(In the table, R1 to R5 are the same as R1 to R5 in the general formula (I).)
[0031]
The production raw material represented by the general formula (II) can be produced stereoselectively according to the following formula.
[Chemical 8]
(In the formula, R 1 and R 2 are the same as R 1 and R 2 in the general formula (I).)
[0032]
(Step 2-1)
This step is a step for producing an epoxy alcohol derivative represented by the general formula (V) by oxidizing the alcohol derivative represented by the general formula (IV).
[0033]
As an oxidation reaction used in this step, for example, a Sharpless oxidation method can be used. As the oxidizing agent, t-butyl hydroperoxide, cumene hydroperoxide, trityl hydroperoxide or the like can be used, and as the catalyst, titanium tetraisopropoxide or the like can be used. Moreover, as an asymmetric source reagent, tartrate ester of optically active substances, such as D-(-)-diisopropyl tartrate, diethyl tartrate, dimethyl tartrate, etc. can be used, for example. The reaction is preferably carried out in an inert solvent. For example, halogenated hydrocarbons such as dichloromethane, chloroform and dichloroethane, and aromatic hydrocarbons such as benzene, toluene and xylene can be used. The reaction can be carried out by gradually raising the temperature from −40 ° C. to room temperature.
[0034]
In this step, the four epoxy alcohol derivatives (V) shown in the following table can be stereoselectively produced by the three-dimensional structure of the alcohol derivative (IV) and the asymmetric reagent.
[Table 2]
(In the table, R1 is the same as R1 in the general formula (I).)
[0035]
(Step 2-2)
This step is a step for producing an epoxycarboxylic acid derivative represented by the general formula (VI) by maintaining the three-dimensional structure by oxidizing the epoxy alcohol derivative represented by the general formula (V). .
[0036]
In the reaction for oxidizing the epoxy alcohol derivative represented by the general formula (V) in this step, an oxidizing reagent such as sodium periodate or periodic acid can be used as an oxidizing agent, and ruthenium chloride can be used as a catalyst. As the reaction solvent, a mixed solvent of acetonitrile / carbon tetrachloride / water is desirably used, and the reaction temperature can be carried out at −10 ° C. to 30 ° C.
[0037]
(Step 2-3)
In this step, the epoxycarboxylic acid derivative represented by the general formula (VIII) is retained by condensing the epoxycarboxylic acid derivative represented by the general formula (VI) and the amine body (VII) to maintain the three-dimensional structure. This is a process for producing an amide derivative.
[0038]
This step is a condensation reaction, and the same condensing agent as in the first step can be used, and the production can be performed with the same reaction reagent and reaction conditions.
[0039]
(Step 2-4)
In this step, the epoxycarboxylic amide derivative represented by the general formula (VIII) is regioselectively opened to produce the azide derivative represented by the general formula (IX) in a stereoselective manner. It is a process.
[0040]
As a ring-opening reagent used in this step, sodium azide-anhydrous magnesium sulfate can be used, and ammonium chloride can be used instead of anhydrous magnesium sulfate. As the reaction solvent, for example, alcohol solvents such as methanol, ethanol, propanol and 2-methoxyethanol, acetonitrile and the like can be used. In addition, reaction can be implemented at 50 to 150 degreeC.
[0041]
In this step, the azide derivative (IX) shown in the following table can be produced in a stereoselective manner corresponding to each steric structure of the epoxycarboxylic acid amide derivative (VIII).
[Table 3]
(In the table, R1 and R2 are the same as R1 and R2 in the general formula (I).)
[0042]
(Step 2-5)
This step is a step of producing an amine derivative represented by the above general formula (II) by reducing the azide derivative represented by the above general formula (IX) to maintain the steric structure.
[0043]
As the reduction reaction used in this step, a catalytic reduction method can be used, and for example, Pd—C, Pd—black or the like can be used as a catalyst. An alcohol solvent such as methanol or ethanol can be used as the reaction solvent, and the reaction temperature can be from room temperature to 40 ° C. Moreover, this process can also reduce using triphenylphosphine and water, and it is preferable to use ether type solvents, such as tetrahydrofuran and a dioxane, as a reaction solvent.
[0044]
The production raw material represented by the general formula (III) can be obtained by protecting the amino group of a commercially available amino acid when X is —N (R 9) — (Izumiya et al. “Basics of Peptide Synthesis”). And Experiment "(1986) Maruzen Co., Ltd.). Further, when X is —O—, the literature (J. Am. Chem. Soc., 86 , 5326 (1964), J.A. Am. Chem. Soc. , 112 , 7659 (1990)).
[0045]
The amino alcohol derivative represented by the general formula (I) can be led to an α-ketoamide derivative (X) having cathepsin K inhibitory activity, for example, by subjecting it to the reaction of the following formula.
[Chemical 9]
(Wherein R1 to R5 are the same as R1 to R5 in the general formula (I)).
[0046]
This step is a step for producing an α-ketoamide derivative represented by the general formula (X) by oxidizing the amino alcohol derivative represented by the general formula (I).
[0047]
As an oxidation reaction used in this step, for example, an active dimethyl sulfoxide oxidation method can be used. As the oxidizing agent, dimethyl sulfoxide is used, and an activator such as dicyclohexylcarbodiimide, phosphorus pentoxide, pyridine-sulfur trioxide complex, oxalyl chloride, acetic anhydride, trifluoroacetic acid or the like is used in combination. The used amount of the activator can be 1 to 12 equivalents relative to the amino alcohol derivative represented by the general formula (I). The reaction is preferably carried out in a solvent. For example, halogenated hydrocarbons such as dichloromethane, chloroform and dichloroethane can be used, but dimethyl sulfoxide used as an oxidizing agent can also be used as an excess solvent. The reaction can be carried out at -78 ° C to 30 ° C.
[0048]
This step corresponds to each steric structure of the amino alcohol derivative (I), and the α-ketoamide derivative (X) shown in the following table can be produced while retaining the steric structure of R1.
[Table 4]
(In the table, R1 to R5 are the same as R1 to R5 in the general formula (I).)
DETAILED DESCRIPTION OF THE INVENTION
Hereinafter, the present invention will be described in more detail with reference examples and examples.
[0049]
Reference example 1
Synthesis of 1-aminocyclohexanecarboxylic acid phenylmethyl ester / p-toluenesulfonate
Embedded image
A Dean-Stark apparatus equipped with a reflux condenser was charged with 50.8 g (355 mmol) of 1-aminocyclohexanecarboxylic acid, 81 g (426 mmol) of p-toluenesulfonic acid monohydrate, 180 ml of benzyl alcohol and 360 ml of toluene. In an oil bath (160 ° C.) overnight. The water formed was removed by azeotropy with toluene. After completion of the reaction, the reaction solution was poured into a large amount of ethyl acetate to precipitate crystals. The crystals were washed again with ethyl acetate to obtain 128 g (89%) of the title compound.
[0050]
1H-NMR (CDCl3, δ): 1.25-1.43 (2H, m), 1.43-1.58 (2H, m), 1.59-1.70 (2H, m), 1. 83-1.94 (2H, m), 1.94-2.02 (2H, m), 2.83 (3H, s), 5.13 (2H, s), 7.10 (2H, d, J = 8Hz), 7.24-7.31 (5H, m), 7.76 (2H, d, J = 8Hz), 8.30 (2H, brs)
IR (ν, KBr, cm −1): 3468, 1746, 1608
FAB-Mass (m / z,%): 406 (M ++ 1, 2), 234 (100)
[0051]
Reference example 2
Synthesis of 1- [N- (morpholine-4-carbonyl) amino] cyclohexanecarboxylic acid phenylmethyl ester
Embedded image
1-Aminocyclohexanecarboxylic acid phenylmethyl ester 203 g (500 mmol) of p-toluenesulfonate was neutralized with 10% sodium carbonate solution, extracted with chloroform, and dried over anhydrous magnesium sulfate. The solid was filtered, and 56 g (550 mmol) of triethylamine was added to the chloroform layer, and then 75 g (500 mmol) of 4-morpholine carbonyl chloride was added dropwise and heated in an oil bath (60 ° C.) for 3 days. After completion of the reaction, the reaction solution was washed with water, 10% aqueous potassium hydrogen sulfate solution, saturated aqueous sodium hydrogen carbonate solution and saturated brine in that order, and dried over anhydrous sodium sulfate. After the solvent was distilled off under reduced pressure, the obtained crystals were washed with ether to obtain 151 g (87%) of the title compound.
[0052]
1H-NMR (CDCl3, δ): 1.22-1.88 (6H, m), 1.85-1.92 (2H, m), 2.07-2.30 (2H, m), 3. 45 (4H, t, J = 5 Hz), 3.67 (4H, t, J = 5 Hz), 4.53 (1H, s), 5.15 (2H, s), 7.31-7.34 ( 5H, m)
IR (ν, KBr, cm −1): 3316, 1732, 1690
FAB-Mass (m / z,%): 347 (M ++ 1, 100), 234 (44)
[0053]
Reference example 3
Synthesis of 1- [N- (morpholine-4-carbonyl) amino] cyclohexanecarboxylic acid
Embedded image
151 g (452 mmol) of 1- [N- (morpholine-4-carbonyl) amino] cyclohexanecarboxylic acid phenylmethyl ester was suspended in methanol, added with 15 g of 5% palladium-activated carbon, and stirred overnight at room temperature under a hydrogen stream. It was. After the catalyst was filtered, the catalyst was washed three times with a mixed solvent of chloroform-methanol, and the organic layers were combined and evaporated under reduced pressure to obtain 112 g (100%) of the title compound.
[0054]
1H-NMR (CDCl3, δ): 1.35-1.39 (3H, m), 1.64-1.72 (3H, m), 1.91-1.97 (2H, m), 2. 06-2.10 (2H, m), 3.43 (4H, t, J = 5Hz), 3.73 (4H, t, J = 5Hz), 4.50 (1H, s)
IR (ν, KBr, cm −1): 3824, 2568, 1970
FAB-Mass (m / z,%): 257 (M ++ 1, 8), 98 (100)
[0055]
Reference example 4
Synthesis of 2-heptin-1-ol
Embedded image
Lithium 6.0 g (0.9 mol) was added to a solution of iron (III) nitrate nonahydrate 180 mg (0.45 mmol) in liquid ammonia 300 ml at -30 to -40 ° C. Further, an ether solution (20 ml) of 2-propyn-1-ol 25.2 g (0.45 mol) was added at the same temperature, and after stirring for 1.5 hours, 41.1 g (0.30 mol) of n-butyl bromide was added. The reaction solution was returned to room temperature and stirred overnight. After completion of the reaction, a saturated aqueous ammonium chloride solution was added, and the mixture was extracted with ether (500 ml). The organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure. The residue was distilled under reduced pressure to give 21.0 g (62.4%) of the title compound.
[0056]
1H-NMR (CDCl3, δ): 0.91 (3H, t, J = 7 Hz), 1.36-1.54 (5H, m), 2.22 (2H, tt, J = 7 Hz, 2 Hz), 4.25 (1H, dt, J = 6Hz, 2Hz)
[0057]
Reference Example 5
Synthesis of (trans) -2-hepten-1-ol
Embedded image
Under ice cooling, 16 ml (53.49 mmol) of a 65% sodium bis (2-methoxyethoxy) aluminum hydride (Red-Al) toluene solution was added to 4.0 g (35.66 mmol) of 2-heptin-1-ol in a toluene solution ( 5 ml), returned to room temperature and stirred for 3 hours. After completion of the reaction, ice water was added and extracted with petroleum ether (50 ml). The organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure. The residue was distilled under reduced pressure to give 3.3 g (80.6%) of the title compound.
[0058]
1H-NMR (CDCl3, δ): 0.90 (3H, t, J = 7 Hz), 1.27-1.41 (5H, m), 2.31 (2H, dt, J = 7 Hz, 6 Hz), 4.09 (2H, dd, J = 5Hz, 5Hz), 5.60-5.74 (2H, m)
[0059]
Reference Example 6
Synthesis of (2R-trans) -3-butyloxiranemethanol
Embedded image
Under an argon atmosphere, 3.4 g of molecular sieves 4A in an anhydrous methylene chloride suspension (150 ml) was added to 3.3 g (14.08 mmol) of D-(-)-diisopropyl tartrate and 3.3 g (11.73 mmol) of titanium tetraisopropoxide. And 13.4 g (117.30 mmol) of 2-hepten-1-ol was added at −30 to −40 ° C. and stirred for 10 minutes. The reaction solution was cooled to −60 ° C., 105 ml of a toluene solution of 2.23M t-butyl hydroperoxide was added dropwise over 20 minutes with stirring, and the temperature was returned to room temperature over 2 hours. After completion of the reaction, the reaction solution was added to an aqueous solution (400 ml) of iron (III) sulfate heptahydrate (80 g) and L-tartaric acid (40 g), and extracted with methylene chloride (400 ml). The organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure. Ether (400 ml) and 1N sodium hydroxide (200 ml) were added to the residue, and the mixture was stirred at room temperature for 1 hour. After completion of the reaction, the organic layer was separated and the aqueous layer was extracted with ether (50 ml). The organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure. The residue was distilled under reduced pressure to give 11.6 g (76.2%) of the title compound.
[0060]
1H-NMR (CDCl3, δ): 0.92 (3H, t, J = 7 Hz), 1.34-1.48 (4H, m), 1.56-1.61 (2H, m), 1. 73 (1H, brs), 2.91-2.98 (2H, m), 3.63 (1H, ddd, J = 12Hz, 8Hz, 4Hz), 3.92 (1H, ddd, J = 12Hz, 6Hz , 3 Hz) IR (ν, NaCl (film), cm −1): 3456, 2936, 2864, 1470, 1030, 880
FAB-Mass (m / z,%): 131 (M ++ 1, 58), 113 (84), 95 (100), 69 (93)
[0061]
Reference Example 7
Synthesis of (2S-trans) -3-butyl-oxiranecarboxylic acid / dicyclohexylamine salt
Embedded image
Under ice cooling, 5.70 g (25 mmol) of periodic acid was added to a mixed solution of 1.30 g (10 mmol) of (2R-trans) -3-butyloxirane methanol in 20 ml of acetonitrile, 20 ml of carbon tetrachloride and 30 ml of water, and then ruthenium chloride. After adding 41 mg of hydrate, the mixture was stirred at room temperature for 1 hour. Ethyl acetate was added to the reaction solution, washed with water and saturated brine, and dried over anhydrous magnesium sulfate. Insoluble matter was filtered off, 1.63 g (9 mmol) of dicyclohexylamine was added to the filtrate, and then the solvent was distilled off under reduced pressure. Petroleum ether was added to the obtained residue and stirred for 2 hours. The crystals were collected by filtration and further washed with petroleum ether to obtain 2.30 g (70%) of the title compound.
[0062]
1H-NMR (CDCl3, δ): 0.91 (3H, t, J = 7 Hz), 1.10-1.30 (6H, m), 1.31-1.57 (9H, m), 1. 58-1.71 (3H, m), 1.74-1.82 (4H, m), 1.96-2.04 (4H, m), 2.90-2.94 (1H, m), 2.97-3.06 (2H, m), 3.08 (1H, d, J = 2Hz)
IR (ν, KBr, cm −1): 2932, 2856, 1604, 1400
FAB-Mass (m / z,%): 326 (M ++ 1, 7), 182 (100)
[0063]
Reference Example 8
Synthesis of (2S-trans) -N-[(1S, 2S) -2-hydroxycyclohexane-1-yl] -3-butyloxiranecarboxamide
Embedded image
Under ice cooling, a solution of 844 mg (7 mmol) of pivaloyl chloride in 2 ml of anhydrous tetrahydrofuran was added to a solution of 2.3 g (7 mmol) of (2S-trans) -3-butyl-oxiranecarboxylic acid, dicyclohexylamine salt in 20 ml of anhydrous tetrahydrofuran. Stir at temperature for 15 minutes. Furthermore, the reaction liquid was returned to room temperature and stirred for 2 hours. The insoluble material in the reaction solution was filtered, and then added to a solution of 806 mg (7 mmol) of (1S, 2S) -2-aminocyclohexanol in 20 ml of anhydrous tetrahydrofuran under ice cooling, followed by stirring at room temperature for 2 hours. The reaction mixture was concentrated under reduced pressure, ethyl acetate was added, and the mixture was washed with 10% aqueous potassium hydrogen sulfate solution, saturated aqueous sodium hydrogen carbonate solution and then saturated brine. The organic layer was dried over anhydrous magnesium sulfate, and the solvent was distilled off under reduced pressure to obtain 1.69 g (100%) of the title compound.
[0064]
1H-NMR (CDCl3, δ): 0.92 (3H, t, J = 7 Hz), 1.11-1.48 (8H, m), 1.52-1.62 (1H, m), 1. 64-1.76 (3H, m), 1.83-1.89 (1H, m), 2.03-2.10 (1H, m), 2.90-2.95 (1H, m), 3.27 (1H, d, J = 2Hz), 3.30-3.38 (1H, m), 3.54-3.65 (1H, m), 6.13 (1H, d, J = 8Hz) )
IR (ν, KBr, cm −1): 2932, 2860, 1650
FAB-Mass (m / z,%): 242 (M ++ 1, 100), 98 (95)
[0065]
Reference Example 9
Synthesis of (2S, 3S) -N-[(1S, 2S) -2-hydroxycyclohexane-1-yl] -3-azido-2-hydroxyheptanamide
Embedded image
(2S) -trans-N-[(1S, 2S) -2-hydroxycyclohexane-1-yl] -3-butyloxiranecarboxamide 1.64 g (7 mmol), sodium azide 910 mg (14 mmol) and anhydrous magnesium sulfate 868 mg ( A suspension of 7.2 mmol) in 30 ml of methanol was heated to reflux for 5 hours. The reaction solution was returned to room temperature, poured into 300 ml of water and stirred for 2 hours. The crystals were collected by filtration, further washed with water and dried to give 1.45 g (73%) of the title compound.
[0066]
1H-NMR (CDCl3, δ): 0.91 (3H, t, J = 7 Hz), 1.19-1.53 (9H, m), 1.58-1.78 (3H, m), 1. 89- 1.98 (1H, m), 2.03-2.11 (1H, m), 3.31-3.39 (1H, m), 3.52 (1H, d, J = 6 Hz), 3.61-3.71 (2H, m), 4.15 (1H, d, J = 4Hz), 4.29 (1H, t, J = 4Hz), 6.78 (1H, d, J = 8Hz) )
IR (ν, KBr, cm −1): 2936, 2864, 2096, 1636
FAB-Mass (m / z,%): 285 (M ++ 1, 100), 116 (97)
[0067]
Reference Example 10
Synthesis of (2S, 3S) -N-[(1S, 2S) -2-hydroxycyclohexane-1-yl] -3-amino-2-hydroxyheptanamide
Embedded image
(2S, 3S) -N-[(1S, 2S) -2-hydroxycyclohexane-1-yl] -3-azido-2-hydroxyheptanamide 1.45 g (5 mmol) in 30 ml of methanol 5% palladium on carbon 150 mg And stirred for 18 hours under hydrogen atmosphere. The insoluble material was filtered, and the filtrate was distilled off under reduced pressure to obtain 1.18 g (91%) of the title compound.
[0068]
1H-NMR (CDCl3, δ): 0.90 (3H, t, J = 7 Hz), 1.18-1.43 (8H, m), 1.51-1.77 (4H, m), 1. 89-1.97 (1H, m), 2.02-2.09 (1H, m), 3.03-3.09 (1H, m), 3.31-3.39 (1H, m), 3.61-3.69 (1H, m), 3,90 (1H, d, J = 6Hz), 7.31 (1H, d, J = 8Hz)
IR (ν, KBr, cm −1): 3344, 2936, 2860, 1650
FAB-Mass (m / z,%): 259 (M ++ 1, 100), 86 (92)
[0069]
Example 1
N-[(2S, 3S) -2-hydroxy-1- [N-[(1S, 2S) -2-hydroxycyclohexane-1-yl] amino] -1-oxo-3-heptyl] -1- [N Synthesis of-(morpholine-4-carbonyl) amino] cyclohexanecarboxamide
Embedded image
Under ice cooling, a solution of 256 mg (1 mmol) of 1- [N- (morpholine-4-carbonyl) amino] cyclohexanecarboxylic acid and 202 mg (2 mmol) of triethylamine in 10 ml of anhydrous tetrahydrofuran was added to a solution of 121 mg (1 mmol) of pivaloyl chloride in 1 ml of anhydrous tetrahydrofuran. And stirred at the same temperature for 2 hours. Furthermore, the reaction liquid was returned to room temperature and stirred for 18 hours. Insoluble matter in the reaction solution was filtered, and 258 mg (1 mmol) of (2S, 3S) -N-[(1S, 2S) -2-hydroxycyclohexane-1-yl] -3-amino-2-hydroxyheptanamide in chloroform was obtained. Added to 80 ml solution and stirred for 3 hours. Chloroform was added to the reaction solution, washed with 10% aqueous potassium hydrogen sulfate solution, saturated aqueous sodium hydrogen carbonate solution and then saturated brine, dried over anhydrous magnesium sulfate, and the solvent was distilled off under reduced pressure. The residue was purified by silica gel column chromatography to obtain 468 mg (94%) of the title compound.
[0070]
1H-NMR (CDCl3, δ): 0.88 (3H, t, J = 7 Hz), 1.17-1.44 (11H, m), 1.45-1.58 (1H, m), 1. 59- 1.77 (6H, m), 1.82-1.97 (4H, m), 2.01-2.07 (2H, m), 3.31-3.44 (5H, m), 3.59-3.69 (1H, m), 3.72 (4H, t, J = 5 Hz), 3.76 (1H, d, J = 4 Hz), 4.05-4.14 (2H, m ), 4.75 (1H, s), 5.02 (1H, d, J = 6 Hz), 6.56 (1H, d, J = 8 Hz), 7.03 (1H, d, J = 8 Hz)
IR (ν, KBr, cm −1): 3380, 2931, 2859, 1675, 1629
FAB-Mass (m / z,%): 497 (M ++ 1, 55), 211 (100)
[0071]
Reference Example 11
N-[(S) -1,2-dioxo-1- [N-[(S) -2-oxocyclohexyl] amino] -3-heptyl] -1- [N- (morpholine-4-carbonyl) amino] Synthesis of cyclohexane carboxamide
Embedded image
A solution of 1.45 g (11.2 mmol) of N, N-diisopropylethylamine and 1.78 g (11.2 mmol) of sulfur trioxide pyridine complex in anhydrous dimethyl sulfoxide (5 ml) and anhydrous methylene chloride (5 ml) at 0 ° C. under a nitrogen stream. It was dripped in. Furthermore, N-[(2S, 3S) -2-hydroxy-1- [N-[(1S, 2S) -2-hydroxycyclohexane-1-yl] amino] -1-oxo-3-heptyl] -1- A solution of 465 mg (0.94 mmol) of [N- (morpholine-4-carbonyl) amino] cyclohexanecarboxamide in anhydrous methylene chloride (5 ml) was added and stirred at 0 ° C. for 3 hours. After completion of the reaction, ice water was added to the reaction solution and extracted with ethyl acetate. The organic layer was washed successively with 10% aqueous citric acid solution, saturated aqueous sodium hydrogen carbonate solution and saturated brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was purified by neutral silica gel column chromatography to obtain 402 mg (87%) of the title compound.
[0072]
1H-NMR (CDCl3, δ): 0.88 (3H, t, J = 7 Hz), 1.23-1.46 (8H, m), 1.55-2.00 (10H, m), 2. 03-2.20 (3H, m), 2.36-2.70 (3H, m), 3.39 (4H, t, J = 5 Hz), 3.72 (4H, t, J = 5 Hz), 4.36-4.47 (1H, m), 4.46 (1H, s), 5.20-5.25 (1H, m), 7.76 (1H, d, J = 6 Hz), 7. 93 (1H, d, J = 7Hz)
IR (ν, KBr, cm −1): 3380, 2931, 2859, 1675, 1629
FAB-Mass (m / z,%): 493 (M ++ 1, 25), 239 (54), 211 (100)
[0073]
Reference Example 12
Synthesis of (2S-trans) -N-[(3,4-methylenedioxy) phenyl] -3-butyloxiranecarboxamide
Embedded image
Under ice cooling, a solution of (2S-trans) -3-butyl-oxiranecarboxylic acid, dicyclohexylamine salt 299 mg (1.84 mmol) in anhydrous tetrahydrofuran 10 ml was added pivaloyl chloride 222 mg (1.84 mmol) in anhydrous tetrahydrofuran 2 ml. The mixture was stirred at the same temperature for 15 minutes. Furthermore, the reaction liquid was returned to room temperature and stirred for 2 hours. The insoluble material in the reaction solution was filtered, and then added to a solution of 252 mg (1.84 mmol) of 3,4-methylenedioxyaniline in 10 ml of anhydrous tetrahydrofuran under ice cooling, followed by stirring at room temperature for 2 hours. The reaction mixture was concentrated under reduced pressure, ethyl acetate was added, and the mixture was washed with 10% aqueous potassium hydrogen sulfate solution, saturated aqueous sodium hydrogen carbonate solution and then saturated brine. The organic layer was dried over anhydrous magnesium sulfate, and the solvent was distilled off under reduced pressure to obtain 484 mg (100%) of the title compound.
[0074]
1H-NMR (CDCl3, δ): 0.93 (3H, t, J = 7 Hz), 1.22-1.51 (4H, m), 1.58-1.80 (2H, m), 3. 05-3.09 (1H, m), 3.33 (1H, d, J = 2Hz), 5.95 (2H, s), 6.74 (1H, d, J = 8Hz), 6.81 ( 1H, dd, J = 8Hz, 2Hz), 7.25 (1H, d, J = 2Hz), 7.72 (1H, s)
IR (ν, NaCl, cm −1): 2932, 2872, 1673
[0075]
Reference Example 13
Synthesis of (2S, 3S) -N-[(3,4-methylenedioxy) phenyl] -3-azido-2-hydroxyheptanamide
Embedded image
484 mg (1.84 mmol) of (2S-trans) -N-[(3,4-methylenedioxy) phenyl] -3-butyloxiranecarboxamide, 239 mg (3.68 mmol) of sodium azide and 228 mg of anhydrous magnesium sulfate (1. 89 mmol) in 30 ml of methanol was heated to reflux for 5 hours. After returning the reaction solution to room temperature, the reaction solution was concentrated under reduced pressure, ethyl acetate was added, and the mixture was washed with water and then saturated brine. The organic layer was dried over anhydrous magnesium sulfate and the solvent was distilled off under reduced pressure. The residue was purified by silica gel column chromatography to obtain 395 mg (70%) of the title compound.
[0076]
1H-NMR (CDCl3, δ): 0.91 (3H, t, J = 7 Hz), 1.30-1.41 (2H, m), 1.42-1.80 (4H, m), 3. 04 (1H, brs), 3.82-3.85 (1H, m), 4.40 (1H, d, J = 4 Hz), 5.96 (2H, s), 6.76 (1H, d, J = 8 Hz), 6.86 (1 H, dd, J = 8 Hz, 2 Hz), 7.27 (1 H, d, J = 2 Hz), 8.32 (1 H, s) IR (ν, NaCl, cm −1 ): 2932, 2872, 2104, 1658
[0077]
Reference Example 14
Synthesis of (2S, 3S) -N-[(3,4-methylenedioxy) phenyl] -3-amino-2-hydroxyheptanamide
Embedded image
To a solution of 395 mg (1.29 mmol) of (2S, 3S) -N-[(3,4-methylenedioxy) phenyl] -3-azido-2-hydroxyheptanamide in 30 ml of methanol was added 40 mg of 5% palladium carbon, hydrogen Stir for 18 hours under atmosphere. Insoluble matter was filtered off, and the filtrate was distilled off under reduced pressure to obtain 344 mg (95%) of the title compound.
[0078]
1H-NMR (CDCl3, δ): 0.91 (3H, t, J = 7 Hz), 1.20-1.75 (6H, m), 3.10 (1H, brs), 3.92 (1H, d, J = 6 Hz), 5.95 (1 H, d, J = 6 Hz), 5.95 (2 H, s), 6.76 (1 H, d, J = 8 Hz), 6.86 (1 H, dd, J = 8Hz, 2Hz), 7.28 (1H, d, J = 2Hz), 9.81 (1H, s)
IR (ν, KBr, cm −1): 3384, 2956, 2872, 1658
[0079]
Example 2
N-[(2S, 3S) -2-hydroxy-1- [N-[(3,4-methylenedioxy) phenyl] amino] -1-oxo-3-heptyl] -1- [N- (morpholine- Synthesis of 4-carbonyl) amino] cyclohexanecarboxamide
Embedded image
(2S, 3S) -N-[(3,4-Methylenedioxy) phenyl] -3-amino-2-hydroxyheptanamide 344 mg (1.23 mmol), 1- [N- (morpholine-4-carbonyl) amino 315 mg (1.23 mmol) of cyclohexanecarboxylic acid and 1-hydroxybenzotriazole 233 (1.48 mmol) were dissolved in anhydrous methylene chloride, followed by 1-ethyl-3- (3-dimethylamino) at 0 ° C. under a nitrogen stream. 284 mg (1.48 mmol) of propyl) carbodiimide was added. Thereafter, the reaction solution was returned to room temperature and stirred overnight. The reaction solution was concentrated under reduced pressure, the residue was dissolved in 80 ml of ethyl acetate, washed successively with water, 10% aqueous potassium hydrogen sulfate solution, saturated aqueous sodium hydrogen carbonate solution and saturated brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography to obtain 574 mg (90%) of the desired product.
[0080]
1H-NMR (CDCl3, δ): 0.88 (3H, t, J = 7 Hz), 1.24-1.42 (6H, m), 1.52-1.72 (10H, m), 1. 80-2.10 (4H, m), 3.32 (4H, t, J = 5 Hz), 3.67 (4H, t, J = 5 Hz), 4.19-4.22 (1H, m), 4.41-4.43 (1H, m), 4.64 (1H, s), 5.50 (1H, d, J = 6 Hz), 5.94 (2H, s), 6.70 (1H, d, J = 8 Hz), 6.89 (1H, dd, J = 8 Hz, 2 Hz), 7.33 (1H, d, J = 2 Hz), 8.69 (1H, s)
IR (ν, KBr, cm −1): 3384, 2932, 2860, 1658
[0081]
Reference Example 15
N-[(S) -1,2-dioxo-1- [N-[(3,4-methylenedioxy) phenyl] amino] -1-oxo-3-heptyl] -1- [N- (morpholine- Synthesis of 4-carbonyl) amino] cyclohexanecarboxamide
Embedded image
Under nitrogen flow, 86,1 mg (6.66 mmol) of N, N-diisopropylethylamine was added dropwise at 0 ° C. to a solution of 1.06 g (6.66 mmol) of sulfur trioxide pyridine complex in anhydrous dimethyl sulfoxide (5 ml) and anhydrous methylene chloride (5 ml). did. Furthermore, N-[(2S, 3S) -2-hydroxy-1- [N- (3,4-methylenedioxyphenyl-1-yl) amino] -1-oxo-3-heptyl] -1- [N A solution of 574 mg (1.11 mmol) of-(morpholine-4-carbonyl) amino] cyclohexanecarboxamide in anhydrous methylene chloride (5 ml) was added, and the mixture was stirred at 0 ° C for 3 hours. After completion of the reaction, ice water was added to the reaction solution and extracted with ethyl acetate. The organic layer was washed successively with 10% aqueous citric acid solution, saturated aqueous sodium hydrogen carbonate solution and saturated brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was purified by neutral silica gel column chromatography to obtain 499 mg (87%) of the title compound.
[0082]
1H-NMR (CDCl3, δ): 0.89 (3H, t, J = 7 Hz), 1.28-1.42 (7H, m), 1.58-1.72 (4H, m), 1. 85-2.17 (5H, m), 3.37 (4H, t, J = 5Hz), 3.71 (4H, t, J = 5Hz), 4.43 (1H, s), 5.20- 5.26 (1H, m), 5.97 (2H, s), 6.77 (1H, d, J = 8Hz), 6.95 (1H, dd, J = 8Hz, 2Hz), 7.35 ( 1H, d, J = 2Hz), 8.06 (1H, d, J = 7Hz), 8.56 (1H, s)
IR (ν, KBr, cm −1): 2928, 2860, 1666
[0083]
Reference Example 16
Synthesis of (2S-trans) -N-butyl-3-butyloxiranecarboxamide
Embedded image
Under ice cooling, a solution of (2S-trans) -3-butyl-oxiranecarboxylic acid, dicyclohexylamine salt 299 mg (1.84 mmol) in anhydrous tetrahydrofuran 10 ml was added pivaloyl chloride 222 mg (1.84 mmol) in anhydrous tetrahydrofuran 2 ml. The mixture was stirred at the same temperature for 15 minutes. Furthermore, the reaction liquid was returned to room temperature and stirred for 2 hours. The insoluble material in the reaction solution was filtered, added to a solution of n-butylamine 135 mg (1.84 mmol) in anhydrous tetrahydrofuran 10 ml under ice cooling, and stirred at room temperature for 2 hours. The reaction mixture was concentrated under reduced pressure, ethyl acetate was added, and the mixture was washed with 10% aqueous potassium hydrogen sulfate solution, saturated aqueous sodium hydrogen carbonate solution and then saturated brine. The organic layer was dried over anhydrous magnesium sulfate, and then the solvent was distilled off under reduced pressure to obtain 366 mg (100%) of the title compound.
[0084]
1H-NMR (CDCl3, δ): 0.93 (3H, t, J = 7 Hz), 0.94 (3H, t, J = 7 Hz), 1.26-1.70 (10H, m), 2. 89-2.93 (1H, m), 3.17-3.25 (3H, m), 6.10 (1H, s)
IR (ν, NaCl, cm −1): 2932, 2872, 1662
[0085]
Reference Example 17
Synthesis of (2S, 3S) -N-butyl-3-azido-2-hydroxyheptanamide
Embedded image
A suspension of 366 mg (1.84 mmol) of (2S-trans) -N-butyl-3-butyloxiranecarboxamide, 239 mg (3.68 mmol) of sodium azide and 228 mg (1.89 mmol) of anhydrous magnesium sulfate in 30 ml of methanol for 5 hours. Heated to reflux. After returning the reaction solution to room temperature, the reaction solution was concentrated under reduced pressure, ethyl acetate was added, and the mixture was washed with water and then saturated brine. The organic layer was dried over anhydrous magnesium sulfate and the solvent was distilled off under reduced pressure. The residue was purified by silica gel column chromatography to obtain 304 mg (68%) of the title compound.
[0086]
1H-NMR (CDCl3, δ): 0.93 (3H, t, J = 7 Hz), 0.95 (3H, t, J = 7 Hz), 1.20-1.70 (10H, m), 2. 86 (1H, d, J = 4 Hz), 3.25-3.35 (2H, m), 3.68-3.72 (1H, m), 4.21 (1H, t, J = 4 Hz), 6.54 (1H, brs)
IR (ν, NaCl, cm −1): 2960, 2872, 2100, 1648
[0087]
Reference Example 18
Synthesis of (2S, 3S) -N-butyl-3-amino-2-hydroxyheptanamide
Embedded image
30 mg of 5% palladium on carbon was added to a solution of 304 mg (1.25 mmol) of (2S, 3S) -N-butyl-3-azido-2-hydroxyheptanamide in 30 ml of methanol and stirred for 18 hours under a hydrogen atmosphere. The insoluble material was filtered off, and the filtrate was distilled off under reduced pressure to obtain 254 mg (94%) of the title compound.
[0088]
1H-NMR (CDCl3, δ): 0.91 (3H, t, J = 7 Hz), 0.93 (3H, t, J = 7 Hz), 1.18-1.80 (10H, m), 3. 01-3.50 (1H, m), 3.23-3.29 (3H, m), 3.83 (1H, d, J = 5 Hz), 7.45 (1H, brs)
IR (ν, KBr, cm −1): 3320, 2932, 2860, 1642
[0089]
Example 3
N-[(2S, 3S) -2-hydroxy-1- [N- (butyl) -amino] -1-oxo-3-heptyl] -1- [N- (morpholine-4-carbonyl) amino] cyclohexanecarboxamide Synthesis of
Embedded image
254 mg (1.21 mmol) of (2S, 3S) -N-butyl-3-amino-2-hydroxyheptanamide, 310 mg (1.21 mmol) of 1- [N- (morpholine-4-carbonyl) amino] cyclohexanecarboxylic acid and 1-Hydroxybenzotriazole 230 (1.45 mmol) was dissolved in anhydrous methylene chloride, and then 278 mg (1.45 mmol) of 1-ethyl-3- (3-dimethylaminopropyl) carbodiimide was added at 0 ° C. under a nitrogen stream. . Thereafter, the reaction solution was returned to room temperature and stirred overnight. The reaction solution was concentrated under reduced pressure, the residue was dissolved in 80 ml of ethyl acetate, washed successively with water, 10% aqueous potassium hydrogen sulfate solution, saturated aqueous sodium hydrogen carbonate solution and saturated brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography to obtain 489 mg (89%) of the desired product.
[0090]
1H-NMR (CDCl3, δ): 0.87 (3H, t, J = 7 Hz), 0.94 (3H, t, J = 7 Hz), 1.24-1.41 (8H, m), 1. 45-1.78 (8H, m), 1.84-1.94 (2H, m), 1.98-2.05 (2H, m), 3.18-3.30 (2H, m), 3.70 (4H, t, J = 5Hz), 3.89 (4H, t, J = 5Hz), 4.10-4.14 (1H, m), 4.26 (1H, dd, J = 6Hz) , 6Hz), 4.65 (1H, s), 5.18 (1H, d, J = 6Hz), 6.73 (1H, d, J = 8Hz), 6.80 (1H, brs)
IR (ν, KBr, cm −1): 3368, 2932, 2860, 1650
[0091]
Reference Example 19
N-[(S) -1,2-dioxo-1- [N- (butyl) amino] -1-oxo-3-heptyl] -1- [N-[(morpholine-4-carbonyl) amino] cyclohexanecarboxamide Synthesis of
Embedded image
Under nitrogen flow, 838 mg (6.48 mmol) of N, N-diisopropylethylamine was added dropwise at 0 ° C. to a solution of 1.03 g (6.48 mmol) of sulfur trioxide pyridine complex in anhydrous dimethyl sulfoxide (5 ml) and anhydrous methylene chloride (5 ml). did. Furthermore, N-[(2S, 3S) -2-hydroxy-1- [N- (butyl) -amino] -1-oxo-3-heptyl] -1- [N- (morpholine-4-carbonyl) amino] A solution of 489 mg (1.08 mmol) of cyclohexanecarboxamide in anhydrous methylene chloride (5 ml) was added, and the mixture was stirred at 0 ° C. for 3 hours. After completion of the reaction, ice water was added to the reaction solution and extracted with ethyl acetate. The organic layer was washed successively with 10% aqueous citric acid solution, saturated aqueous sodium hydrogen carbonate solution and saturated brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was purified by neutral silica gel column chromatography to obtain 415 mg (85%) of the title compound.
[0092]
1H-NMR (CDCl3, δ): 0.88 (3H, t, J = 7 Hz), 0.93 (3H, t, J = 7 Hz), 1.22-1.42 (9H, m), 1. 49-1.70 (6H, m), 1.85-2.00 (3H, m), 2.06-2.15 (2H, m), 3.26-3.38 (2H, m), 3.38 (4H, t, J = 5Hz), 3.72 (4H, t, J = 5Hz), 4.44 (1H, s), 5.17-5.20 (1H, m), 6. 86 (1H, t, J = 6Hz), 7.94 (1H, d, J = 7Hz)
IR (ν, KBr, cm −1): 3344, 2932, 2860, 1658
[0093]
Reference Example 20
Synthesis of (2S-trans) -N-[(2S) -1-methoxy-1-oxo-3-phenyl-2-propyl] -3-butyloxiranecarboxamide
Embedded image
Under ice cooling, a solution of (2S-trans) -3-butyl-oxiranecarboxylic acid, dicyclohexylamine salt 299 mg (1.84 mmol) in anhydrous tetrahydrofuran 10 ml was added pivaloyl chloride 222 mg (1.84 mmol) in anhydrous tetrahydrofuran 2 ml. The mixture was stirred at the same temperature for 15 minutes. Furthermore, the reaction liquid was returned to room temperature and stirred for 2 hours. After filtering insoluble matters in the reaction solution, 187 mg (1.84 mmol) of triethylamine was added under ice cooling, 397 mg (1.84 mmol) of L-phenylalanine methyl ester hydrochloride was added, and the mixture was stirred at room temperature for 2 hours. . The reaction mixture was concentrated under reduced pressure, ethyl acetate was added, and the mixture was washed with 10% aqueous potassium hydrogen sulfate solution, saturated aqueous sodium hydrogen carbonate solution and then saturated brine. The organic layer was dried over anhydrous magnesium sulfate, and then the solvent was distilled off under reduced pressure to obtain 558 mg (100%) of the title compound.
[0094]
1H-NMR (CDCl3, δ): 0.91 (3H, t, J = 7 Hz), 1.20-1.45 (4H, m), 1.46-1.63 (2H, m), 2. 58-2.61 (1H, m), 3.01 (1H, dd, J = 14Hz, 7Hz), 3.16 (1H, d, J = 2Hz), 3.20 (1H, dd, J = 14Hz , 7Hz), 3.74 (3H, s), 4.81-4.87 (1H, m), 6.48 (1H, d, J = 8Hz), 7.05-7.10 (2H, m ), 7.24-7.31 (3H, m)
IR (ν, NaCl, cm −1): 2960, 2868, 1684
[0095]
Reference Example 21
Synthesis of (2S, 3S) -N-[(2S) -1-methoxy-1-oxo-3-phenyl-2-propyl] -3-azido-2-hydroxyheptanamide
Embedded image
(2S) -trans-N-[(2S) -1-methoxy-1-oxo-3-phenyl-2-yl] -3-butyloxiranecarboxamide 558 mg (1.84 mmol), sodium azide 239 mg (3.68 mmol) ) And anhydrous magnesium sulfate (228 mg, 1.89 mmol) in methanol (30 ml) were heated to reflux for 5 hours. After returning the reaction solution to room temperature, the reaction solution was concentrated under reduced pressure, ethyl acetate was added, and the mixture was washed with water and then saturated brine. The organic layer was dried over anhydrous magnesium sulfate and the solvent was distilled off under reduced pressure. The residue was purified by silica gel column chromatography to obtain 442 mg (69%) of the title compound.
[0096]
1H-NMR (CDCl3, δ): 0.90 (3H, t, J = 7 Hz), 1.21-1.62 (6H, m), 2.87 (1H, d, J = 4 Hz), 3. 09 (1H, dd, J = 14Hz, 7Hz), 3.16 (1H, dd, J = 14Hz, 7Hz), 3.59-3.63 (1H, m), 3.75 (3H, s), 4.20 (1H, dd, J = 4Hz, 4Hz), 4.88-4.93 (1H, m), 7.00 (1H, d, J = 8Hz), 7.14 (2H, d, J = 8Hz), 7.25-7.33 (3H, m)
IR (ν, KBr, cm −1): 2856, 2100, 1658
[0097]
Reference Example 22
Synthesis of (2S, 3S) -N-[(2S) -1-methoxy-1-oxo-3-phenyl-2-propyl] -3-amino-2-hydroxyheptanamide
Embedded image
To a solution of 442 mg (1.27 mmol) of (2S, 3S) -N-[(2S) -1-methoxy-1-oxo-3-phenyl-2-propyl] -3-azido-2-hydroxyheptanamide in 30 ml of methanol 45% 5% palladium carbon was added and stirred for 18 hours under hydrogen atmosphere. Insoluble matter was filtered off, and the filtrate was distilled off under reduced pressure to obtain 385 mg (94%) of the title compound.
[0098]
1H-NMR (CDCl3, δ): 0.89 (3H, t, J = 7 Hz), 1.18-1.70 (6H, m), 2.86-2.91 (1H, m), 3. 06 (1H, dd, J = 14Hz, 7Hz), 3.18 (1H, dd, 14Hz, 7Hz), 3.73 (3H, s), 3.76 (1H, d, J = 7Hz), 4. 86-4.92 (1H, m), 7.15 (1H, d, J = 7Hz), 7.21-7.31 (5H, m), 8.15 (1H, d, J = 8Hz)
IR (ν, KBr, cm −1): 3364, 2956, 2860, 1652
[0099]
Example 4
N-[(2S, 3S) -2-hydroxy-1- [N-[(2S) -1-methoxy-1-oxo-3-phenyl-2-propyl] amino] -1-oxo-3-heptyl] Synthesis of -1- [N- (morpholine-4-carbonyl) amino] cyclohexanecarboxamide
Embedded image
(2S, 3S) -N-[(2S) -1-methoxy-1-oxo-3-phenyl-2-yl] -3-amino-2-hydroxyheptanamide 385 mg (1.19 mmol), 1- [N -(Morpholine-4-carbonyl) amino] cyclohexanecarboxylic acid 305 mg (1.19 mmol) and 1-hydroxybenzotriazole 226 (1.43 mmol) were dissolved in anhydrous methylene chloride, followed by 1-hydroxybenzoic acid at 0 ° C. under a nitrogen stream. 274 mg (1.43 mmol) of ethyl-3- (3-dimethylaminopropyl) carbodiimide was added. Thereafter, the reaction solution was returned to room temperature and stirred overnight. The reaction solution was concentrated under reduced pressure, the residue was dissolved in 80 ml of ethyl acetate, washed successively with water, 10% aqueous potassium hydrogen sulfate solution, saturated aqueous sodium hydrogen carbonate solution and saturated brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography to obtain 587 mg (88%) of the title compound.
[0100]
1H-NMR (CDCl3, δ): 0.86 (3H, t, J = 7 Hz), 1.20-1.70 (12H, m), 1.80-1.90 (2H, m), 1. 92-2.02 (2H, m), 3.05-3.17 (2H, m), 3.36 (4H, t, J = 5Hz), 3.69 (4H, t, J = 5Hz), 3.70 (3H, s), 4.09-4.14 (1H, m), 4.34 (1H, dd, J = 6Hz, 6Hz), 4.63 (1H, s), 4.80- 4.86 (1H, m), 5.00 (1H, d, J = 6Hz), 6.57 (1H, d, J = 8Hz), 7.14 (1H, d, J = 8Hz), 7. 20-7.30 (5H, m)
IR (ν, KBr, cm −1): 3392, 2932, 2860, 1658
[0101]
Reference Example 23
N-[(S) -1,2-dioxo-1- [N-[(2S) -1-methoxy-1-oxo-3-phenyl-2-propyl] amino] -1-oxo-3-heptyl] Synthesis of -1- [N-[(morpholine-4-carbonyl) amino] cyclohexanecarboxamide
Embedded image
Under nitrogen flow, 814 mg (6.30 mmol) of N, N-diisopropylethylamine was added dropwise at 0 ° C. to a solution of 1.00 g (6.30 mmol) of sulfur trioxide pyridine complex in anhydrous dimethyl sulfoxide (5 ml) and anhydrous methylene chloride (5 ml). did. Furthermore, N-[(2S, 3S) -2-hydroxy-1- [N-[(2S) -1-methoxy-1-oxo-3-phenyl-2-propyl] amino] -1-oxo-3- A solution of 587 mg (1.05 mmol) of heptyl] -1- [N- (morpholine-4-carbonyl) amino] cyclohexanecarboxamide in anhydrous methylene chloride (5 ml) was added and stirred at 0 ° C. for 3 hours. After completion of the reaction, ice water was added to the reaction solution and extracted with ethyl acetate. The organic layer was washed successively with 10% aqueous citric acid solution, saturated aqueous sodium hydrogen carbonate solution and saturated brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was purified by neutral silica gel column chromatography to obtain 487 mg (83%) of the title compound.
[0102]
1H-NMR (CDCl3, δ): 0.87 (3H, t, J = 7 Hz), 1.20-1.42 (7H, m), 1.54-1.76 (4H, m), 1. 80-1.96 (3H, m), 2.05-2.18 (2H, m), 3.06-3.18 (2H, m), 3.36 (4H, t, J = 5 Hz), 3.71 (4H, t, J = 5 Hz), 3.72 (3H, s), 4.46 (1H, d, J = 6 Hz), 4.80-4.85 (1H, m), 5. 17-5.19 (1H, m), 7.09 (1H, d, J = 8Hz), 7.12 (1H, dd, J = 8Hz, 2Hz), 7.23-7.31 (4H, m ), 7.96 (1H, d, J = 7Hz)
IR (ν, KBr, cm −1): 2932, 2860, 1678
[0103]
Example 5
(2S) -N-[(2S, 3S) -2-hydroxy-1- [N-[(1S, 2S) -2-hydroxycyclohexane-1-yl] amino] -1-oxo-3-heptyl]- Synthesis of 2- (2-methylcarbonyloxy) -3-phenylpropylamide
Embedded image
(S)-[2-acetyloxy-3-phenyl] propanoic acid 1.0 g (5.5 mmol), (2S, 3S) -N-[(1S, 2S) -2-hydroxycyclohexane-1-yl]- 1.4 g (5.5 mmol) of 3-amino-2-hydroxyheptanamide and 1.0 g (6.6 mmol) of 1-hydroxybenzotriazole were dissolved in 20 ml of methylene chloride, and 1-ethyl-3- (3- 1.3 g (6.6 mmol) of dimethylaminopropyl) carbodiimide was added and stirred for 18 hours. The solvent was distilled off under reduced pressure, ethyl acetate was added to the residue, washed with 10% aqueous potassium hydrogen sulfate solution, saturated aqueous sodium hydrogen carbonate solution and saturated brine, dried over anhydrous magnesium sulfate and evaporated under reduced pressure. . The residue was purified by silica gel column chromatography to obtain 2.2 g (84%) of the title compound.
[0104]
1H-NMR (CDCl3, δ): 0.84 (3H, t, J = 7 Hz), 0.99-1.37 (8H, m), 1.43-1.58 (2H, m), 1. 68-1.74 (2H, m), 2.01-2.10 (1H, m), 2.07 (3H, s), 3.10 (1H, dd, J = 14 Hz, 7 Hz), 3. 17 (1H, dd, J = 14Hz, 6Hz), 3.38 (1H, dt, J = 10Hz, 4Hz), 3.55-3.62 (1H, m), 3.97-4.03 (1H m), 4.16 (1H, s), 4.97 (1H, brs), 5.24 (1H, dd, J = 7Hz, 6Hz), 6.35 (1H, d, J = 8Hz), 6.93 (1H, d, J = 8Hz), 7.18-7.31 (5H, m)
IR (ν, KBr, cm −1): 3314, 2935, 1671, 1636
[0105]
Reference Example 24
(2S) -N-[(S) -1,2-dioxo-1- [N-[(S) -2-oxocyclohexyl] amino] -3-heptyl] -2- (acetyloxy) -3-phenylpropi Synthesis of Luamide
Embedded image
Under a nitrogen stream, 700 mg (5.4 mmol) of N, N-diisopropylethylamine was added dropwise at 0 ° C. to a solution of 854 mg (5.4 mmol) of sulfur trioxide pyridine complex in anhydrous dimethyl sulfoxide (20 ml) and anhydrous methylene chloride (15 ml). Further, (2S) -N-[(2S, 3S) -2-hydroxy-1- [N-[(1S, 2S) -2-hydroxycyclohexane-1-yl] amino] -1-oxo-3-heptyl ] A solution of 200 mg (0.45 mmol) of 2- (acetyloxy) -3-phenylpropylamide in anhydrous methylene chloride (5 ml) was added, and the mixture was stirred at 0 ° C for 3 hours. After completion of the reaction, ice water was added to the reaction solution and extracted with ethyl acetate. The organic layer was washed successively with 10% aqueous citric acid solution, saturated aqueous sodium hydrogen carbonate solution and saturated brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was washed with ether to obtain 115 mg (58%) of the title compound.
[0106]
1H-NMR (CDCl3, δ): 0.85 (3H, t, J = 7 Hz), 1.10-1.94 (10H, m), 2.10 (3H, s), 2.15-2. 20 (1H, m), 2.43 (1H, dt, J = 13 Hz, 6 Hz), 2.56-2.68 (2H, m), 3.07 (1H, dd, J = 14 Hz, 7 Hz), 3.32 (1H, dd, J = 14Hz, 5Hz), 4.38-4.44 (1H, m), 5.26 (1H, dt, J = 8Hz, 5Hz), 5.39 (1H, dd , J = 7Hz, 5Hz), 6.55 (1H, d, J = 8Hz), 7.16-7.29 (5H, m), 7.75 (1H, d, J = 6Hz)
IR (ν, KBr, cm −1): 3334, 2934, 2862, 1740, 1671
[0107]
Example 6
(2S) -N-[(2S, 3S) -2-hydroxy-1- [N-[(1S, 2S) -2-hydroxycyclohexane-1-yl] amino] -1-oxo-3-heptyl]- Synthesis of 4-methyl-2- [N- (phenylmethoxycarbonyl) amino] pentanamide
Embedded image
Under a stream of argon gas at 0 ° C, a solution of 761 mg (1.1 mmol) of L-N-phenylmethoxycarbonylleucine in 25 ml of anhydrous tetrahydrofuran was added to 0.23 ml (1.9 mmol) of pivaloyl chloride, and then (2S, 3S) -N- [ A suspension of (1S, 2S) -2-hydroxycyclohexane-1-yl] -3-amino-2-hydroxyheptanamide 400 mg (1.5 mmol) in anhydrous tetrahydrofuran-chloroform (5: 3) was added dropwise. Stir at warm for 2 hours. Furthermore, the reaction liquid was returned to room temperature and stirred for 10 hours. After completion of the reaction, 30 ml of saturated aqueous ammonium chloride was added to the reaction solution, and tetrahydrofuran and chloroform were distilled off. The residue was extracted three times with 50 ml of 5% methanol / chloroform. The organic layers were combined, washed with 100 ml of saturated aqueous sodium hydrogen carbonate solution and then with 100 ml of saturated brine, dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was recrystallized from 35 ml of ethanol-diethyl ether (5: 2) to obtain 210 mg (26.8%) of the title compound.
[0108]
1H-NMR (DMSO-d6, δ): 0.79 (3H, t, J = 7 Hz), 0.85 (3H, d, J = 7 Hz), 0.87 (3H, d, J = 7 Hz), 1.04-1.31 (9H, m), 1.34-1.50 (3H, m), 1.52-1.66 (3H, m), 1.76-1.87 (2H, m ), 3.26-3.42 (2H, m), 3.84 (1H, dd, J = 6 Hz, 3 Hz), 4.00-4.13 (2H, m), 4.51 (1H, d , J = 5 Hz), 5.02 (2H, s), 5.71 (1H, d, J = 6 Hz), 7.28-7.40 (6H, m), 7.43 (1H, d, J = 8Hz), 7.47 (1H, d, J = 9Hz)
IR (ν, KBr, cm −1): 3322, 2937, 1660, 1531
[0109]
Reference Example 25
(2S) -N-[(S) -1,2-dioxo-1- [N-[(S) -2-oxocyclohexyl] amino] -3-heptyl] -4-methyl-2- [N- ( Synthesis of phenylmethoxycarbonyl) amino] pentanamide
Embedded image
Under a stream of argon gas at 0 ° C., sulfur trioxide pyridine complex 567 mg (3.6 mmol) in anhydrous dimethyl sulfoxide-methylene chloride (1: 1) in 4 ml solution diisopropylethylamine 0.62 ml (3.6 mmol), then (2S)- N-[(2S, 3S) -2-hydroxy-1- [N-[(1S, 2S) -2-hydroxycyclohexane-1-yl] amino] -1-oxo-3-heptyl] -4-methyl- A solution of 150 mg (0.3 mmol) of 2- [N- (phenylmethoxycarbonyl) amino] pentanamide in 2 ml of anhydrous dimethyl sulfoxide was added dropwise and stirred at the same temperature for 5 hours. After completion of the reaction, 25 ml of ice water was added to the reaction solution and extracted three times with 20 ml of ethyl acetate. The organic layers were combined, washed with 10% -citric acid aqueous solution 50 ml, saturated sodium hydrogen carbonate aqueous solution 50 ml, then saturated brine 50 ml, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was subjected to neutral silica gel column chromatography to obtain 120 mg of the title compound from the eluate of hexane-ethyl acetate (11: 9), and recrystallized from 5 ml of ethyl acetate-hexane (3: 2) to give 90 mg of the title compound ( 60.5%).
[0110]
1H-NMR (CDCl3, δ): 0.87 (3H, t, J = 7 Hz), 0.94 (6H, d, J = 6 Hz), 1.20-1.55 (6H, m), 1. 58-1.74 (4H, m), 1.74-1.87 (1H, m), 1.87-2.00 (2H, m), 2.12-2.21 (1H, m), 2.40 (1H, dt, J = 14 Hz, 6 Hz), 2.53-2.61 (1H, m), 2.61-2.70 (1H, m), 4.16-4.25 (1H m), 4.37-4.45 (1H, m), 5.08-5.18 (3H, m), 5.28 (1H, dt, J = 8Hz, 5Hz), 6.54 (1H , d, J = 8 Hz), 7.29-7.40 (5H, m), 7.77 (1H, d, J = 6 Hz)
IR (ν, KBr, cm −1): 3320, 1689, 1661, 1526
[0111]
Example 7
(2S) -N-[(2S, 3S) -2-hydroxy-1- [N-[(1S, 2S) -2-hydroxycyclohexane-1-yl] amino] -1-oxo-3-heptyl]- Synthesis of 1- (phenylmethoxycarbonyl) pyrrolidine-2-carboxamide
Embedded image
L-N-phenylmethoxycarbonylproline 523 mg (2.1 mmol), (2S, 3S) -N-[(1S, 2S) -2-hydroxycyclohexane-1-yl] -3-amino-2-hydroxyheptanamide 518 mg (2.0 mmol) and 338 mg (2.2 mmol) of 1-hydroxybenzotriazole were dissolved in 20 ml of dimethylformamide, and 423 mg (2.2 mmol) of 1-ethyl-3- (3-dimethylaminopropyl) carbodiimide was added under ice cooling. And stirred for 18 hours. 1N Hydrochloric acid was added to the reaction solution, and the mixture was extracted with chloroform. The organic layer was washed with a saturated aqueous sodium hydrogen carbonate solution and then with saturated brine, dried over anhydrous magnesium sulfate, and the solvent was distilled off under reduced pressure. The residue was purified by silica gel column chromatography to obtain 709 mg (72%) of the title compound.
[0112]
1H-NMR (DMSO-d6, δ): 0.68 (1.8H, t, J = 7 Hz), 0.80 (1.2H, t, J = 7 Hz), 0.94 to 1.44 (10H) , m), 1.52-1.64 (2H, m), 1.74-1.94 (5H, m), 1.97-2.18 (1H, m), 3.26-3.49 (4H, m), 3.81-3.86 (1H, m), 4.00-4.09 (1H, m), 4.23 (0.4H, dd, J = 8 Hz, 3 Hz), 4 .30 (0.6H, dd, J = 8Hz, 3Hz), 4.50 (1H, d, J = 5Hz), 4.93-5.11 (2H, m), 5.70 (0.4H, d, J = 5 Hz), 5.75 (0.6 H, d, J = 5 Hz), 7.24-7.40 (6 H, m), 7.62 (0.4 H, d, J = 9 Hz), 7.70 (0.6H, d, J = 9Hz)
IR (ν, KBr, cm −1): 3401, 2933, 1664, 1637
[0113]
Reference Example 26
(2S) -N-[(S) -1,2-dioxo-1- [N-[(S) -2-oxocyclohexyl] amino] -3-heptyl] -1- (phenylmethoxycarbonyl) pyrrolidine-2 -Synthesis of carboxamide
Embedded image
Dioxyethylamine 1.47 ml (8.6 mmol) in a solution of sulfur trioxide pyridine complex 1.38 g (8.6 mmol) in anhydrous dimethyl sulfoxide-methylene chloride (1: 1) at 0 ° C. under an argon gas stream, and then ( 2S) -N-[(2S, 3S) -2-hydroxy-1- [N-[(1S, 2S) -2-hydroxycyclohexane-1-yl] amino] -1-oxo-3-heptyl] -1 A solution of 350 mg (0.7 mmol) of-(phenylmethoxycarbonyl) pyrrolidine-2-carboxamide in 5 ml of anhydrous dimethyl sulfoxide was added dropwise and stirred at the same temperature for 5 hours. After completion of the reaction, 25 ml of ice water was added to the reaction solution and extracted three times with 30 ml of ethyl acetate. The organic layers were combined, washed with 10% -citric acid aqueous solution 100 ml, saturated sodium hydrogen carbonate aqueous solution 100 ml, then saturated brine 100 ml, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by neutral silica gel column chromatography to obtain 300 mg (86.1%) of the title compound.
[0114]
1H-NMR (DMSO-d6, δ): 0.77 (1.8H, t, J = 7 Hz), 0.86 (1.2H, t, J = 7 Hz), 1.12-1.58 (6H , m), 1.63-1.92 (7H, m), 1.96-2.05 (1H, m), 2.07-2.24 (2H, m), 2.27-2.34 (1H, m), 2.48-2.58 (1H, m), 3.32-3.48 (2H, m), 4.28 (0.4H, dd, J = 9 Hz, 3 Hz), 4 .33 (0.6H, dd, J = 9Hz, 3Hz), 4.39-4.47 (1H, m), 4.95 (1H, ddd, J = 9Hz, 7Hz, 3Hz), 4.99- 5.11 (2H, m), 7.25-7.40 (5H, m), 8.28 (0.4H, d, J = 7Hz), 8.32 (0.6H, d, J = 7Hz) ), 8.53 (0.4H, d, J = 8Hz), 8.55 (0.6H, d, J = 8Hz)
IR (ν, KBr, cm −1): 3320, 2935, 2863, 1704, 1666
[0115]
【The invention's effect】
According to the present invention, a novel aminoalcohol derivative can be provided, and the derivative is used as a production intermediate capable of leading to a very economical and stereoselective useful α-ketoamide derivative having protease inhibitory activity. Can do.
Claims (2)
(工程4)式(VIII):
(工程5)上記工程4で製造された式(IX)で表されるアジド誘導体を還元することにより、立体構造を保持して、式(II):
(工程6)上記工程5で製造された式(II)で表されるアミン誘導体と式(III):
を含む、方法(式中、R1及びR2は、同一若しくは異なって、置換若しくは無置換の炭素数1〜12の直鎖状、分枝鎖状若しくは環状のアルキル基、置換若しくは無置換の芳香族炭化水素基又は置換若しくは無置換の複素環基である。R3は置換若しくは無置換の炭素数1〜12の直鎖状、分枝鎖状若しくは環状のアルキル基、置換若しくは無置換の炭素数2〜6の直鎖状、分枝鎖状若しくは環状のアルケニル基、置換若しくは無置換の芳香族炭化水素基、置換若しくは無置換の複素環基、R6−O−又はR7−N(R8)−である。R6は、置換若しくは無置換の炭素数1〜12の直鎖状、分枝鎖状若しくは環状のアルキル基、置換若しくは無置換の炭素数2〜6の直鎖状、分枝鎖状若しくは環状のアルケニル基、置換若しくは無置換の芳香族炭化水素基又は置換若しくは無置換の複素環基である。R7及びR8は同一若しくは異なって、水素原子、置換若しくは無置換の炭素数1〜12の直鎖状、分枝鎖状若しくは環状のアルキル基、置換若しくは無置換の炭素数2〜6の直鎖状、分枝鎖状若しくは環状のアルケニル基、置換若しくは無置換の芳香族炭化水素基又は置換若しくは無置換の複素環基である。さらに、R4及びR5は一体となって炭素原子数6の飽和環状アルキル基を形成する。Xは−NH−である。)。Formula (I):
(Step 4) Formula (VIII):
(Step 5) By reducing the azide derivative represented by the formula (IX) produced in the above step 4, the steric structure is maintained, and the formula (II):
Wherein R1 and R2 are the same or different and each represents a substituted or unsubstituted linear, branched or cyclic alkyl group having 1 to 12 carbon atoms , a substituted or unsubstituted aromatic group, A hydrocarbon group or a substituted or unsubstituted heterocyclic group, and R3 is a substituted or unsubstituted linear, branched or cyclic alkyl group having 1 to 12 carbon atoms , a substituted or unsubstituted carbon number of 2; -6 linear, branched or cyclic alkenyl groups, substituted or unsubstituted aromatic hydrocarbon groups, substituted or unsubstituted heterocyclic groups, R6-O- or R7-N (R8)- R6 represents a substituted or unsubstituted linear, branched or cyclic alkyl group having 1 to 12 carbon atoms , a substituted or unsubstituted linear or branched chain group having 2 to 6 carbon atoms , Cyclic alkenyl group, substituted or unsubstituted aromatic carbonization A hydrogen group or a substituted or unsubstituted heterocyclic group, R7 and R8 are the same or different and each represents a hydrogen atom, a substituted or unsubstituted linear, branched or cyclic alkyl group having 1 to 12 carbon atoms; , substituted or unsubstituted 2-6 carbon atoms linear, branched or cyclic alkenyl group, a substituted or unsubstituted aromatic hydrocarbon group or a substituted or unsubstituted heterocyclic group. further, R4 and R5 together form a saturated cyclic alkyl group having 6 carbon atoms, X is -NH-).
(工程1)式(IV):
(工程2)上記工程1で製造された式(V)で表されるエポキシアルコール誘導体を酸化することにより、立体構造を保持して、式(VI):
(工程3)上記工程2で製造された式(VI)で表されるエポキシカルボン酸誘導体と式(VII):R2NH2で表されるアミン体を縮合することにより、立体構造を保持して、式(VIII):
をさらに含む、請求項1記載の方法(式中、R1、R2、R3、R4、R5、及びXは請求項1に定義されたとおりである)。Before steps 4, 5, and 6,
(Step 1) Formula (IV):
(Step 2) By oxidizing the epoxy alcohol derivative represented by the formula (V) produced in the above step 1, the three-dimensional structure is maintained, and the formula (VI):
(Step 3) By condensing the epoxycarboxylic acid derivative represented by the formula (VI) produced in the above Step 2 and the amine body represented by the formula (VII): R 2 NH 2 , the steric structure is maintained. Formula (VIII):
The method of claim 1, further comprising: wherein R 1 , R 2 , R 3 , R 4 , R 5 , and X are as defined in claim 1.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2001172689A JP4666440B2 (en) | 2000-06-30 | 2001-06-07 | Amino alcohol derivative |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2000198091 | 2000-06-30 | ||
JP2000-198091 | 2000-06-30 | ||
JP2001172689A JP4666440B2 (en) | 2000-06-30 | 2001-06-07 | Amino alcohol derivative |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2002080438A JP2002080438A (en) | 2002-03-19 |
JP4666440B2 true JP4666440B2 (en) | 2011-04-06 |
Family
ID=26595084
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2001172689A Expired - Fee Related JP4666440B2 (en) | 2000-06-30 | 2001-06-07 | Amino alcohol derivative |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP4666440B2 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2646123A1 (en) * | 2006-03-16 | 2007-09-27 | Vertex Pharmaceuticals Incorporated | Processes and intermediates for preparing steric compounds |
RU2446157C2 (en) * | 2006-09-13 | 2012-03-27 | Санофи-Авентис | Isoserine derivatives applied as blood coagulation factor ixa inhibitors |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1990012805A1 (en) * | 1989-04-15 | 1990-11-01 | Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai | Postostatin and related compound thereof, or their salts |
WO1999017778A1 (en) * | 1997-10-07 | 1999-04-15 | Cephalon Inc. | α-KETOAMIDE MULTICATALYTIC PROTEASE INHIBITORS |
JPH11514330A (en) * | 1995-01-06 | 1999-12-07 | シビア・ニユーロサイエンシズ・インコーポレイテツド | Peptide and peptide analog protease inhibitors |
JP2003526634A (en) * | 1999-12-03 | 2003-09-09 | ブリストル−マイヤーズ スクイブ ファーマ カンパニー | Α-Ketoamide inhibitors of hepatitis C virus NS3 protease |
EP1008592B1 (en) * | 1998-11-12 | 2006-02-01 | Seikagaku Corporation | Cyclic amide derivatives which inhibit cathepsin K |
-
2001
- 2001-06-07 JP JP2001172689A patent/JP4666440B2/en not_active Expired - Fee Related
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1990012805A1 (en) * | 1989-04-15 | 1990-11-01 | Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai | Postostatin and related compound thereof, or their salts |
JPH11514330A (en) * | 1995-01-06 | 1999-12-07 | シビア・ニユーロサイエンシズ・インコーポレイテツド | Peptide and peptide analog protease inhibitors |
WO1999017778A1 (en) * | 1997-10-07 | 1999-04-15 | Cephalon Inc. | α-KETOAMIDE MULTICATALYTIC PROTEASE INHIBITORS |
EP1008592B1 (en) * | 1998-11-12 | 2006-02-01 | Seikagaku Corporation | Cyclic amide derivatives which inhibit cathepsin K |
JP2003526634A (en) * | 1999-12-03 | 2003-09-09 | ブリストル−マイヤーズ スクイブ ファーマ カンパニー | Α-Ketoamide inhibitors of hepatitis C virus NS3 protease |
Also Published As
Publication number | Publication date |
---|---|
JP2002080438A (en) | 2002-03-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8163943B2 (en) | Epoxycarboxamide compound, azide compound, and amino alcohol compound, and process for preparing α-keto amide compound using them | |
US10647744B2 (en) | Tripeptide epoxy ketone protease inhibitors | |
CA2389685C (en) | Novel heterocyclic compounds and their use as medicaments | |
FR2609716A1 (en) | NOVEL PEPTIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | |
JP3892187B2 (en) | Cyclic amide derivative | |
JP4666440B2 (en) | Amino alcohol derivative | |
HU213621B (en) | Process for preparing beta-phenylisoserine derivatives | |
WO2006064286A1 (en) | Cathepsin s inhibitors | |
JP4421141B2 (en) | Azide derivatives | |
KR102365509B1 (en) | Tripeptide epoxy ketone protease inhibitors | |
JP2002179664A (en) | Epoxycarboxylic acid amide derivative | |
JP3490441B2 (en) | N- (hydroxyethyl) butanediamide derivatives as renin inhibitors | |
JP4265993B2 (en) | Novel carboxylic acid derivatives | |
JP4312657B2 (en) | Novel hydroxy carboxamide derivatives | |
JP4312656B2 (en) | Novel hydroxycarboxylic acid derivatives | |
JP4312672B2 (en) | New carboxylic acid derivatives | |
JP2004277427A (en) | Carboxylic acid derivative | |
JP2012136437A (en) | Heterocyclic 5-membered ring compound | |
JP2005029470A (en) | New norstatine derivative | |
JP2005104860A (en) | Synthesis of cyclic nonprotein-constituting amino acid | |
JP2006225344A (en) | 2-acylaminomethyl-3,4-dihydroxypyrrolidine type enzyme inhibitor | |
KR20040050060A (en) | An intermediate of an optically active diarylalanine, its derivatives and process for prepararing the same | |
FR2809398A1 (en) | New N-heterocyclyl secondary amine compounds, useful for treating diseases associated with calpains and reactive oxygen species, and their intermediates | |
FR2800737A1 (en) | New heterocyclic amine compounds have calpain inhibiting and reactive oxygen species capturing activity, useful for treatment of inflammatory and immunological disorders | |
KR20030063813A (en) | An intermediate of an optically active diarylalanine, its derivatives and process for prepararing the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20051221 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090804 |
|
RD13 | Notification of appointment of power of sub attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7433 Effective date: 20090910 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20091002 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20090911 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20091124 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100223 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20100224 |
|
A911 | Transfer of reconsideration by examiner before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20100318 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100824 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20101022 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20110105 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20110106 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140121 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |